0001437749-23-004919 | 10-K | XBRL Viewer | Horizon Technology Finance Corp

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1. Organization

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income (including net capital gains) the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the Nasdaq Global Select Market under the symbol “HRZN”.

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

The Company formed Horizon Funding 2019‑1 LLC (“2019‑1 LLC”) as a Delaware limited liability company on May 2, 2019 and Horizon Funding Trust 2019‑1 on May 15, 2019 (“2019‑1 Trust” and, together with the 2019‑1 LLC, the “2019‑1 Entities”). The 2019‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2019‑1 Entities for purposes of securitizing the 2019 Asset-Backed Notes.

The Company and Arena Sunset SPV, LLC ("Arena") formed Horizon Funding I, LLC (“HFI”) as a Delaware limited liability company on May 9, 2018, with Horizon Secured Loan Fund I LLC, a Delaware limited liability company ("HSLFI") as its sole member. HFI is a special purpose bankruptcy-remote entity and is a separate legal entity from HSLFI. Any assets conveyed to HFI are not available to creditors of HSLFI or any other entity other than HFI’s lenders.

On April 21, 2020, the Company purchased all of the limited liability company interests of Arena in HSLFI, including, without limitation, undistributed amounts owed to Arena and interest accrued and unpaid on the debt investments of HSLFI through the date of purchase. As of April 21, 2020, HSLFI and its subsidiary, HFI, are consolidated by the Company.

The Company formed Horizon Funding 2022‑1 LLC (“2022‑1 LLC”) as a Delaware limited liability company on September 30, 2022 and Horizon Funding Trust 2022‑1 on October 18, 2022 (“2022‑1 Trust” and, together with the 2022‑1 LLC, the “2022‑1 Entities”). The 2022‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2022‑1 Entities for purposes of securitizing the 2022 Asset-Backed Notes.

The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy, which is a separate legal entity from the Company.

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

Note 2 - Basis of Presentation and Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 2. Basis of presentation and significant accounting policies

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑K and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications, consisting solely of normal recurring accruals, that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated.

Principles of consolidation

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements. Although the Company owned more than 25% of the voting securities of HSLFI through April 21, 2020, the Company did not have sole control over significant actions of HSLFI for purposes of the 1940 Act or otherwise, and thus did not consolidate its interest prior to April 21, 2020.

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

Use of estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair value

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

See Note 6 for additional information regarding fair value.

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investments

Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Company's board of directors (the “Board”) oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. As of December 31, 2021, there was one investment on non-accrual status with a cost of $11.5 million and a fair value of $6.9 million. For the year ended December 31, 2022, the Company did not recognize any interest income from debt investments on non-accrual status. For the year ended December 31, 2021, the Company recognized, as interest income, payments of $1.3 million received from two portfolio companies whose debt investments were on non-accrual status. For the year ended December 31, 2020, the Company recognized, as interest income, payments of $0.03 million received from one portfolio company whose debt investment was on non-accrual status.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the years ended December 31, 2022, 2021 and 2020 was 7.4%, 5.9% and 5.8%, respectively.

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Prior to consolidating the investment in HSLFI on and after April 21, 2020, distributions from HSLFI were evaluated at the time of distribution to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company did not record distributions from HSLFI as dividend income unless there was sufficient accumulated tax-basis earnings and profit in HSLFI prior to distribution. Distributions that were classified as a return of capital were recorded as a reduction in the cost basis of the investment. For the period January 1, 2020 through April 21, 2020, HSLFI made no distributions classified as dividend income or a return of capital to the Company.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt issuance costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of December 31, 2022 and 2021 was $7.1 million and $4.3 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of December 31, 2022 and 2021 were $4.8 million and $3.2 million, respectively. The amortization expense for the years ended December 31, 2022, 2021 and 2020 was $1.6 million, $1.1 million and $1.0 million, respectively.

Income taxes

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the years ended December 31, 2022, 2021 and 2020, the Company reclassified $0.7 million, $0.4 million and $0.2 million, respectively, to paid-in capital from distributions in excess of net investment income, which related to excise taxes payable.

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the years ended December 31, 2022, 2021 and 2020, $0.7 million, $0.4 million and $0.2 million, respectively, was recorded for U.S. federal excise tax.

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at December 31, 2022 and 2021. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.

Stockholders’ Equity

On August 2, 2019, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2019 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc., (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2019 Equity Distribution Agreement provided that the Company may offer and sell shares of common stock from time to time through the Sales Agents representing up to $50.0 million worth of its common stock, in amounts and at times to be determined by the Company.

On July 30, 2020, the Company entered into an ATM sales agreement (the “2020 Equity Distribution Agreement”), with the Sales Agents. The 2020 Equity Distribution Agreement provided that the Company may offer and sell shares of common stock from time to time through the Sales Agents representing up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company.

On August 2, 2021, the Company terminated the 2020 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2021 Equity Distribution Agreement”) with the Sales Agents. The remaining shares available under the 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement are no longer available for issuance. The 2021 Equity Distribution Agreement provides that the Company may offer and sell our shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of its common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NASDAQ or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

On March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

During the year ended December 31, 2022, the Company sold 3,982,684 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $50.3 million, including $1.0 million of offering expenses, from these sales. During the year ended December 31, 2021, the Company sold 1,907,234 shares of common stock under the 2021 Equity Distribution Agreement and the 2020 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $30.1 million, including $0.8 million of offering expenses, from these sales. During the year ended December 31, 2020, the Company sold 3,702,500 shares of common stock under the 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $44.6 million, including $1.0 million of offering expenses, from these sales.

The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of December 31, 2022, shares representing approximately $31.5 million of its common stock remain available for issuance and sale under the Equity Distribution Agreement.

Stock Repurchase Program

On April 29, 2022, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2023 or the repurchase of $5.0 million of the Company’s common stock. During the years ended December 31, 2022, 2021 and 2020, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through December 31, 2022, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

Transfers of financial assets

Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

Recently adopted accounting pronouncement

In March 2020, the FASB issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. As of December 31, 2022, the Company adopted ASU 2020-04, and such adoption did not have an impact on the Company's consolidated financial statements and disclosures.

Recently issued accounting pronouncement

In June 2022, the FASB issues Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

Note 3 - Related Party Transactions

12 Months Ended

Dec. 31, 2022

Note 3. Related party transactions

Investment Management Agreement

At a special meeting of the stockholders on October 30, 2018, the stockholders approved a new Investment Management Agreement which became effective on March 7, 2019. The new Investment Management Agreement replaced the previously effective Amended and Restated Investment Management Agreement dated as of October 28, 2010 and amended effective July 1, 2014. On October 28, 2022, the Board unanimously approved the renewal of the Investment Management Agreement. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the SEC. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

The base management fee was and will be calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 million, the base management fee on the amount of such excess over $250 million will be calculated at an annual rate of 1.60% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage. The base management fee is payable monthly in arrears and is prorated for any partial month.

The base management fee payable at December 31, 2022 and 2021 was $1.1 million and $0.7 million, respectively. The base management fee expense was $10.6 million, $7.6 million and $6.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.

The incentive fee has two parts, as follows:

The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s pre-incentive fee net investment income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a hurdle rate of 1.75% (which is 7.00% annualized) of the Company’s net assets at the end of the immediately preceding calendar quarter, adjusted for any share issuances or repurchases during the relevant quarter, subject to a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875% quarterly (which is 8.75% annualized). The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.

Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.

The net performance based incentive fee expense was $7.7 million, $7.1 million and $5.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap and Deferral Mechanism for the year ended December 31, 2022, which resulted in $1.0 million of reduced expense and additional net investment income. This deferral represents a contingent future liability and may be paid up to three years after the date of deferment. The incentive fee on Pre-Incentive Fee Net Investment Income was not subject to the Incentive Fee Cap and Deferral Mechanism for the years ended December 31, 2021 and 2020. The performance based incentive fee payable at December 31, 2022 and 2021 was $1.4 million and $2.0 million, respectively. The entire incentive fee payable at December 31, 2022 and 2021 represented part one of the incentive fee.

Administration Agreement

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $1.7 million, $1.3 million and $1.0 million for years ended December 31, 2022, 2021 and 2020, respectively.

Note 4 - Investments

12 Months Ended

Dec. 31, 2022

Investment Holdings [Text Block]

Note 4. Investments

The following table shows the Company’s investments as of December 31, 2022 and 2021:

	*December 31, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Investments
Debt	$	701,074	$	686,458	$	441,885	$	437,317
Warrants		14,790		29,712		10,023		20,200
Other		1,200		1,300		1,450		200
Equity		4,184		2,556		479		358
Total investments	$	721,248	$	720,026	$	453,837	$	458,075

The following table shows the Company’s investments by industry sector as of December 31, 2022 and 2021:

	*December 31, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Life Science
Biotechnology	$	193,372	$	195,006	$	109,899	$	107,902
Medical Device		132,803		135,960		88,681		84,567
Technology
Communications		22,892		26,176		22,853		25,920
Consumer-Related		121,961		114,050		92,158		93,194
Data Storage		476		1,316		476		1,047
Internet and Media		329		1,159		569		3,305
Networking		11,831		11,710		17,390		17,964
Power Management		1,585		2,610		1,585		2,609
Semiconductors		56		—		101		—
Software		120,157		118,716		60,902		60,807
Sustainability
Energy Efficiency		8		27		—		—
Other Sustainability		84,633		85,524		46,595		47,011
Healthcare Information and Services
Diagnostics		9,851		9,858		12,393		12,377
Other		7,559		3,870		175		1,177
Software		13,735		14,044		60		195
Total investments	$	721,248	$	720,026	$	453,837	$	458,075

Horizon Secured Loan Fund I LLC

On June 1, 2018, the Company and Arena formed a joint venture, HSLFI, to make investments, either directly or indirectly through subsidiaries, primarily in secured loans to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. HSLFI was formed as a Delaware limited liability company and was not consolidated by either the Company or Arena for financial reporting purposes. On April 21, 2020, the Company purchased all of the limited liability company interests of Arena in HSLFI, including, without limitation, undistributed amounts owed to Arena and interest accrued and unpaid on the debt investments of HSLFI through the date of purchase, for $17.1 million. In addition, Arena received 50% of the warrants held by HSLFI or HFI at closing. As of April 21, 2020, HSLFI is wholly-owned by the Company and the assets and liabilities of HSLFI and HFI will be consolidated with the assets and liabilities of the Company. The transaction is accounted for as an asset acquisition under GAAP.

During the period January 1, 2020 through April 21, 2020, there were no distributions from HSLFI.

HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to a sale and servicing agreement with HFI, as Issuer, and the Company, as Servicer (the “Sale and Servicing Agreement”), as amended by that certain Amendment No. 1 to the Sale and Servicing Agreement, dated June 19, 2019 (the “Amendment No. 1”). Any notes issued by HFI were collateralized by all investments held by HFI and permitted an advance rate of up to 67% of the aggregate principal amount of eligible debt investments. The notes were issued pursuant to that certain indenture by and between HFI and U.S. Bank National Association, dated as of June 1, 2018 (the “Indenture”). Prior to June 5, 2020, the interest rate on the notes issued under the NYL Facility was based on the three year USD mid-market swap rate plus a margin of between 2.75% and 3.25% depending on the rating of such notes at the time of issuance.

The following tables show certain summarized financial information for HSLFI for the period January 1, 2020 through April 21, 2020:

	For the period
	January 1, 2020
	through
	April 21, 2020
	(In thousands)
Selected Statements of Operations Information
Interest income on investments	$	1,353
Total investment income	$	1,465
Total expenses	$	1,229
Net investment income	$	236
Net realized gain on investments	$	120
Net unrealized depreciation on investments	$	(392	)
Net decrease in net assets resulting from operations	$	(36	)

Note 5 - Transactions With Affiliated Companies

12 Months Ended

Dec. 31, 2022

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

Note 5. Transactions with affiliated companies

A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities.

For the year ended December 31, 2022, there were no transactions related to investments in non-controlled affiliated companies.

Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2021 were as follows:

					Year ended December 31, 2021
	*Fair value at*							*Transfers*					*Net*						*Fair value at*
Portfolio	*December 31,*				*Principal*			*in/(out) at*			*Discount*		*unrealized*			*Net realized*			*December 31,*		*Interest*
Company	*2020*		*Purchases*		*Payments*			*fair value*			*accretion*		*gain/(loss)*			*gain/(loss)*			*2021*		*income*
	(In thousands)
Decisyon, Inc. ⁽¹⁾	$	1,181	$	—	$	—		$	(1,181	)	$	—	$	—		$	—		$	—	$	41
		626		—		—			(638	)		12		—			—			—		21
		227		—		—			(227	)		—		—			—			—		7
		228		—		—			(228	)		—		—			—			—		7
		685		—		—			(685	)		—		—			—			—		22
		276		—		—			(276	)		—		—			—			—		9
		183		—		—			(183	)		—		—			—			—		6
		120		—		—			(120	)		—		—			—			—		—
MVI (ABC) LLC fka StereoVision, Inc.		2,382		—		(2,783	)		—			—		—			401			—		139
		—		250		(250	)		—			—		—			—			—		—
		—		70		(70	)		—			—		—			—			—		—
		—		330		(330	)		—			—		—						—		—
		—		150		(150	)		—			—		—			—			—		—
		1,639		—		—			—			—		(848	)		(791	)		—		—
Total non-controlled affiliates	$	7,547	$	800	$	(3,583	)	$	(3,538	)	$	12	$	(848	)	$	(390	)	$	—	$	252

(1)	As of December 31, 2021 the Company no longer owns 5% or more of the portfolio company.

A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). Transactions related to investments in controlled affiliated companies for the year ended December 31, 2022 were as follows:

					*Year ended December 31, 2022*

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*		*Net realized*			*December 31,*		*Dividend*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*		*gain/(loss)*			*2022*		*income*
	(In thousands)
HESP LLC		—		—		(300	)		—		—		1,450		(1,150	)		—		—
Total controlled affiliates	$	—	$	—	$	(300	)	$	—	$	—	$	1,450	$	(1,150	)	$	—	$	—

Transactions related to investments in controlled affiliated companies for the year ended December 31, 2021 were as follows:

					Year ended December 31, 2021

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*			*Net realized*		*December 31,*		*Dividend*
Company	*2020*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*			*gain/(loss)*		*2021*		*income*
	(In thousands)
HESP LLC		1,500		—		(50	)		—		—		(1,450	)		—		—		—
Total controlled affiliates	$	1,500	$	—	$	(50	)	$	—	$	—	$	(1,450	)	$	—	$	—	$	—

Note 6 - Fair Value

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Text Block]

Note 6. Fair value

Prior to July 30, 2022, the Board determined the fair value of the Company’s investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of the Company’s investments, based on input of the Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by the Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Level 1

Quoted prices in active markets for identical assets and liabilities.

Level 2

Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money market funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt investments: The fair value of debt investments is estimated by discounting the expected future cash flows using the year end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

●

Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

●

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

●

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

●

Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment.

●

Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or initial public offerings, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other investments: Other investments are valued based on the facts and circumstances of the underlying contractual agreement. The Company currently values these contractual agreements using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized these other investments as Level 3 within the fair value hierarchy described above. These other investments are recorded at fair value on a recurring basis.

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of the Company's investments as of December 31, 2022 and 2021. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of December 31, 2022:

*December 31, 2022*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*
			(Dollars in thousands, except per share data)
Debt investments	$	669,617	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 22%		14	%

		16,545	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 75%		31	%

		296	Convertible Note Analysis	Price Per Share	$168.93	$	168.93

Warrant investments		26,145	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	58.52
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3

Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%

Equity investments		2,416	Last Equity Financing	Price Per Share	$1.00– $215.03	$	26.93

Total Level 3 investments	$	716,319

(1)	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

December 31, 2021
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average⁽¹⁾
			(Dollars in thousands, except per share data)
Debt investments	$	430,417	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 23%		12	%

		6,900	Multiple Probability Weighted Cash Flow Model	Probability Weighting	20% - 50%		33	%

Warrant investments		19,837	Black-Scholes Valuation Model	Price Per Share	0.000 –980.0000	$	20.35
				Average Industry Volatility	25%		25	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 4		2

Other investments		200	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	0% – 100%		100	%

Equity investments		203	Last Equity Financing	Price Per Share	0.000 –1.0000	$	0.41

Total Level 3 investments	$	457,557

(1)	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Borrowings: The Key Facility and the NYL Facility approximate fair value due to the variable interest rate of the facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed-rate 2026 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On December 31, 2022, the closing price of the 2026 Notes on the New York Stock Exchange was $23.45 per note and had an aggregate fair value of $53.9 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. The fair value of the fixed-rate 2027 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On December 31, 2022, the closing price of the 2027 Notes on the New York Stock Exchange was $23.20 per note and had an aggregate fair value of $53.4 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on December 31, 2022, the 2019 Asset-Backed Notes (as defined in Note 7) were trading at par value, or $42.6 million, and are categorized as Level 3 within the fair value hierarchy described above. Based on market quotations on December 31, 2022, the 2022 Asset-Backed Notes (as defined in Note 7) were trading at par value, or $100.0 million, and are categorized as Level 3 within the fair value hierarchy described above. These borrowings are not recorded at fair value on a recurring basis.

Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

The following tables detail the assets that are carried at fair value and measured at fair value on a recurring basis as of December 31, 2022 and 2021 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	*December 31, 2022*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Investments in money market funds	$	—	$	7,066	$	—	$	7,066
Restricted investments in money market funds	$	—	$	2,788	$	—	$	2,788
Debt investments	$	—	$	—	$	686,458	$	686,458
Warrant investments		—		3,567		26,145		29,712
Other investments		—		—		1,300		1,300
Equity investments		140		—		2,416		2,556
Total investments	$	140	$	3,567	$	716,319	$	720,026

	December 31, 2021
	Level 1		Level 2		Level 3		Total
	(In thousands)
Investments in money market funds	$	—	$	7,868	$	—	$	7,868
Restricted investments in money market funds	$	—	$	1,359	$	—	$	1,359
Debt investments	$	—	$	—	$	437,317	$	437,317
Warrant investments		—		363		19,837		20,200
Other investments		—		—		200		200
Equity investments		155		—		203		358
Total investments	$	155	$	363	$	457,557	$	458,075

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the year ended December 31, 2022:

	*Year ended December 31, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203		$	200		$	457,557
Purchase of investments		421,372			—			606			—			421,978
Warrants and equity received and classified as Level 3		—			5,664			8			—			5,672
Principal payments received on investments		(95,558	)		—			—			(313	)		(95,871	)
Proceeds from sale of investments		(49,371	)		(464	)		—			—			(49,835	)
Net realized (loss) gain on investments		(8,221	)		264			—			(1,137	)		(9,094	)
Unrealized (depreciation) appreciation included in earnings		(10,044	)		2,215			(401	)		1,350			(6,880	)
Transfer out of Level 3		—			(1,371	)		—						(1,371	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(5,837	)		—			—			—			(5,837	)
Level 3 assets, end of period	$	686,458		$	26,145		$	2,416		$	1,300		$	716,319

During the year ended December 31, 2022, there were three transfers out of Level 3. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $0.04 million that was transferred to Level 2 upon the portfolio company becoming a public company. Two transfers out of Level 3 related to the conversion of warrants to equity held in two portfolio companies with an aggregate fair value of $1.3 million that were transferred to Level 1 upon the portfolio companies becoming a public companies. During the year ended December 31, 2022, there was one transfer in to Level 3. The transfer in related to warrants held in one portfolio company with an aggregate fair value of less than $0.01 million that was transferred to Level 3 upon the portfolio company becoming a private company.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at December 31, 2022 includes $21.0 million in unrealized depreciation on debt and other investments, $2.6 million in unrealized appreciation on warrant investments, and $0.4 million in unrealized depreciation on equity investments.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the year ended December 31, 2021:

	*Year ended December 31, 2021*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	333,495		$	12,736		$	2,117		$	1,700		$	350,048
Purchase of investments		344,445			—			—			—			344,445
Warrants and equity received and classified as Level 3		—			2,681			—			—			2,681
Principal payments received on investments		(188,010	)		—			—			—			(188,010	)
Proceeds from sale of investments		(47,436	)		(3,241	)		—			(13	)		(50,690	)
Net realized (loss) gain on investments		(5,033	)		2,514			—			—			(2,519	)
Unrealized appreciation (depreciation) included in earnings		1,836			5,218			(1,682	)		(1,487	)		3,885
Transfer out of Level 3		—			(71	)		(232	)		—			(303	)
Other		(1,980	)		—			—			—			(1,980	)
Level 3 assets, end of period	$	437,317		$	19,837		$	203		$	200		$	457,557

During the year ended December 31, 2021, there were three transfers out of Level 3. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $0.1 million that was transferred to Level 2 upon the portfolio company becoming a public company. One transfer out of Level 3 related to equity held in one portfolio company with an aggregate fair value of $0.1 million that was transferred to Level 1 upon the portfolio company becoming a public company. One transfer out of Level 3 related to equity held in one portfolio company with an aggregate fair value of $0.2 million that was transferred to Level 1 upon the portfolio company being acquired by a public company.

The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at December 31, 2021 includes $5.6 million in unrealized depreciation on debt and other investments and $6.3 million in unrealized appreciation on warrant investments.

The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of December 31, 2022 and 2021, all of the balances of all the Company’s financial instruments were recorded at fair value, except for the Company’s borrowings, as previously described.

Market risk

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 7 - Borrowings

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Text Block]

Note 7. Borrowings

The following table shows the Company’s borrowings as of December 31, 2022 and 2021:

	*December 31, 2022*							*December 31, 2021*
	*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*
	*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*
	(In thousands)
Key Facility	$	125,000	$	5,000		$	120,000	$	125,000	$	53,500		$	71,500
NYL Facility		200,000		176,750			23,250		100,000		78,750			21,250
2019 Asset-Backed Notes		42,573		42,573			—		70,500		70,500			—
2022 Asset-Backed Notes		100,000		100,000			—		—		—			—
2027 Notes		57,500		57,500			—		—		—			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		582,573		439,323			143,250		353,000		260,250			92,750
Unamortized debt issuance costs attributable to term borrowings		—		(5,245	)		—		—		(2,637	)		—
Total borrowings outstanding, net	$	582,573	$	434,078		$	143,250	$	353,000	$	257,613		$	92,750

As of December 31, 2022, with certain limited exceptions the Company, as a BDC is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 150% after such borrowings. As of December 31, 2022, the asset coverage for borrowed amounts was 172%.

Credit Facilities

Key Facility

The Company entered into the Key Facility with Key effective November 4, 2013. On June 22, 2021, the Company amended the Key Facility, among other things, to amend the interest rate applied to the outstanding principal balance and to extend the period during which we may request advances under the Key Facility to June 22, 2024. The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million from the $125 million commitment. The Key Facility is collateralized by all debt investments and warrants held by Credit II and permits an advance rate of up to 60% of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and includes portfolio company concentration limits as defined in the related loan agreement. The Key Facility is scheduled to mature on June 22, 2026. Through June 21, 2021, the interest rate on the Key Facility was based upon the one-month LIBOR plus a spread of 3.25%, with a LIBOR floor of 1.00%. From and after June 30, 2021, the interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was 7.50% and 3.25% on December 31, 2022 and December 31, 2021, respectively. The average interest rate for the years ended December 31, 2022 and 2021 was 5.33% and 4.25%, respectively. The Key Facility requires the payment of an unused line fee in an amount up to 0.50% on an annualized basis of any unborrowed amount available under the facility. As of December 31, 2022 and 2021, the Company had borrowing capacity under the Key Facility of $120.0 million and $71.5 million, respectively. At December 31, 2022 and 2021, $40.2 million and $19.8 million, respectively, was available for borrowing, subject to existing terms and advance rates.

NYL Facility

On April 21, 2020, the Company purchased all of the limited liability company interests of Arena in HSLFI, which is a party to the NYL Facility. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments. The notes were issued pursuant to the Indenture. The interest rate on the notes issued under the NYL Facility was based on the three year USD mid-market swap rate plus a margin of between 3.55% and 5.15% with an interest rate floor, depending on the rating of such notes at the time of issuance.

On February 25, 2022, the Company amended its NYL Facility, increasing the commitment by $100.0 million to enable its wholly-owned subsidiary to issue up to $200.0 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2023 and the maturity date to June 2028. In addition, the amendment, among other things, reduces the applicable margin used to calculate the credit facility’s interest rate on the Company’s borrowings above $100.0 million. Such borrowings will be priced at the three-year USD mid-market swap rate plus 3.00%.

There were $176.8 million and $78.8 million in advances made by the NYL Noteholders as of December 31, 2022 and 2021, respectively. The interest rate as of December 31, 2022 and 2021 was 5.57% and 4.62%, respectively. As of December 31, 2022 and December 31, 2021, the Company had borrowing capacity under the NYL Facility of $23.2 and $21.2 million, respectively. At December 31, 2022 and December 31, 2021, $23.2 and $5.7 million, respectively, was available for borrowing, subject to existing terms and advance rates.

Under the terms of the NYL Facility, the Company required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. The Company has segregated these funds and classified them as restricted investments in money market funds. At December 31, 2022 and 2021, there were approximately $1.0 million and $0.5 million, respectively, of restricted investments..

Securitizations

2019 Asset-Backed Notes

On August 13, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2019 Asset-Backed Notes. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC. There has been no change in the rating since August 13, 2019.

The 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2019 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The reinvestment period of the 2019 Asset-Backed Notes ended July 15, 2021 and the maturity is September 15, 2027.

As of December 31, 2022 and 2021, the 2019 Asset-Backed Notes had an outstanding principal balance of $42.6 million and $70.5 million, respectively.

Under the terms of the 2019 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2019 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2019 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At December 31, 2022 and 2021, there were approximately $0.6 million and $0.9 million of restricted investments, respectively.

2022 Asset-Backed Notes

On November 9, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2022 Asset-Backed Notes. The 2022 Asset-Backed Notes were rated A by DRBS, Inc. There has been no change in the rating since November 9, 2022.

The 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The reinvestment period of the Asset-Backed Notes ends November 15, 2024 and the maturity is November 15, 2030.

As of December 31, 2022, the 2022 Asset-Backed Notes had an outstanding principal balance of $100.0 million.

Under the terms of the 2022 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At December 31, 2022, there were approximately $1.0 million of restricted investments.

Unsecured Notes

2022 Notes

On September 29, 2017, the Company issued and sold an aggregate principal amount of $32.5 million of 6.25% notes due in 2022 and on October 11, 2017, pursuant to the underwriters’ 30-day option to purchase additional notes, the Company sold an additional $4.9 million of such notes (collectively, the “2022 Notes”). The 2022 Notes had a stated maturity of September 15, 2022 and were redeemable in whole or in part at the Company’s option at any time or from time to time on or after September 15, 2019 at a redemption price of $25 per security plus accrued and unpaid interest. The 2022 Notes bore interest at a rate of 6.25% per year, payable quarterly on March 15, June 15, September 15 and December 15 of each year. The 2022 Notes were the Company’s direct unsecured obligations and (i) ranked equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) were senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2022 Notes; (iii) were effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) were structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. On April 24, 2021 (the “Redemption Date”), the Company redeemed all of the issued and outstanding 2022 Notes in an aggregate principal amount of $37.4 million and paid accrued interest of $0.3 million. The Company accelerated $0.4 million of unamortized debt issuance costs related to the 2022 Notes. The 2022 Notes were delisted effective on the Redemption Date.

2026 Notes

On March 30, 2021, the Company issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026 (the “2026 Notes”). The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of December 31, 2022, the Company was in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

2027 Notes

On June 15, 2022, the Company issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30-day option to purchase additional notes, the Company sold an additional $7.5 million of such notes (collectively, the “2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of December 31, 2022, the Company was in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

The following table shows information about our senior securities as of December 31, 2022, 2021, 2020, 2019 and 2018:

	*Total Amount*
	*Outstanding*				*Involuntary*		*Average*
	*Exclusive of*		*Asset*		*Liquidation*		*Market*
	*Treasury*		*Coverage*		*Preference*		*Value per*
Class and Year	*Securities(1)*		*per Unit(2)*		*per Unit(3)*		*Unit(4)*
	(In thousands, except unit data)
Credit facilities
2022	$	181,750	$	4,169		—		N/A
2021	$	132,250	$	3,823		—		N/A
2020	$	50,250	$	7,965		—		N/A
2019	$	17,000	$	19,908		—		N/A
2018	$	90,500	$	2,896		—		N/A
2027 Notes
2022	$	57,500	$	13,179		—	$	24.09
2026 Notes
2022	$	57,500	$	13,179		—	$	24.45
2021	$	57,500	$	8,793		—	$	25.90
2022 Notes
2022	$	—	$	—		—		N/A
2021	$	—	$	—		—		N/A
2020	$	37,375	$	10,708		—	$	24.60
2019	$	37,375	$	9,055		—	$	25.53
2017	$	37,375	$	7,014			$	25.52
2022-1 Securitization
2022	$	100,000	$	7,578		—		N/A
2019-1 Securitization
2022	$	42,573	$	17,799		—		N/A
2021	$	70,500	$	7,171		—		N/A
2020	$	100,000	$	4,002		—		N/A
2019	$	100,000	$	3,384		—		N/A
Total senior securities
2022	$	439,323	$	1,725		—		N/A
2021	$	260,250	$	1,943		—		N/A
2020	$	187,625	$	2,133		—		N/A
2019	$	154,375	$	2,192		—		N/A
2018	$	127,875	$	2,050		—		N/A

(1)	Total amount of senior securities outstanding at the end of the period presented.

(2)

Asset coverage per unit is the ratio of the original cost less accumulated depreciation, amortization or impairment of the Company’s total consolidated assets, less all liabilities and indebtedness not represented by senior securities, to the aggregate amount of senior securities representing indebtedness. Asset coverage per unit is expressed in terms of dollar amounts per $1,000 of indebtedness.

(3)

The amount which the holder of such class of senior security would be entitled upon the voluntary liquidation of the applicable issuer in preference to any security junior to it. The “ — ” in this column indicates that the SEC expressly does not require this information to be disclosed for certain types of securities.

(4)	Not applicable to the Company’s credit facilities, 2019‑1 Securitization and 2022-1 Securitization because such securities are not registered for public trading.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Note 8 - Federal Income Tax

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Text Block]

Note 8. Federal income tax

The Company has elected to be treated as a RIC under Subchapter M of the Code and to distribute substantially all of its taxable income. Accordingly, no provision for federal, state or local income tax has been recorded in the financial statements. Taxable income differs from net increase in net assets resulting from operations primarily due to unrealized appreciation on investments as investment gains and losses are not included in taxable income until they are realized.

The following table reconciles net increase in net assets resulting from operations to taxable income:

	*Years Ended December 31,*
	*2022*		*2021*			*2020*
	(In thousands)
Net increase in net assets resulting from operations	$	21,151	$	27,782		$	6,364
Net unrealized depreciation (appreciation) on investments		5,552		(3,205	)		(313	)
Other book-tax differences		3,292		1,462			782
Change in capital loss carry forward		9,484		3,643			14,698
Taxable income before deductions for distributions	$	39,479	$	29,682		$	21,531

The tax characters of distributions paid are as follows:

	*Years Ended December 31,*
	*2022*		*2021*		*2020*
	(In thousands)
Ordinary income	$	31,490	$	25,099	$	21,592
Total	$	31,490	$	25,099	$	21,592

The components of undistributed ordinary income earnings on a tax basis were as follows:

	*As of December 31,*
	*2022*			*2021*			*2020*
	(In thousands)
Undistributed ordinary income	$	18,813		$	10,825		$	6,242
Long term capital loss carry forward		(73,055	)		(63,571	)		(59,928	)
Unrealized appreciation		18,542			12,973			9,578
Unrealized depreciation		(19,771	)		(8,738	)		(8,545	)
Other temporary differences		11,875			7,465			5,983
Total	$	(43,596	)	$	(41,046	)	$	(46,670	)

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% excise tax on such income, as required. For the years ended December 31, 2022 and 2021, the Company elected to carry forward taxable income in excess of current year distributions of $18.8 million and $10.8 million, respectively. At December 31, 2022 and 2021, a provision for excise tax of $0.7 million and $0.4 million, respectively was recorded.

Capital losses in excess of capital gains earned in a tax year may generally be carried forward, without expiration, and used to offset capital gains, subject to certain limitations. During the years ended December 31, 2022, 2021 and 2020, the Company did not use any material capital loss carry forwards to offset capital gains.

For federal income tax purposes, the tax cost of investments at December 31, 2022 and 2021 was $721.2 million and $453.8 million, respectively. The gross unrealized appreciation on investments at December 31, 2022 and 2021 was $18.5 million and $13.0 million, respectively. The gross unrealized depreciation on investments at December 31, 2022 and 2021 was $19.8 million and $8.7 million, respectively.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Note 9 - Financial Instruments With Off-balance-sheet Risk

12 Months Ended

Dec. 31, 2022

Financial Instruments Disclosure [Text Block]

Note 9. Financial instruments with off-balance-sheet risk

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was $190.0 million and $114.5 million as of December 31, 2022 and 2021, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements.

The following table provides the Company’s unfunded commitments by portfolio company as of December 31, 2022:

	*December 31, 2022*
			*Fair Value of*
			*Unfunded*
	*Principal*		*Commitment*
	*Balance*		*Liability*
	(In thousands)
BrightInsight, Inc.	$	21,000	$	278
Britecore Holdings, Inc.		5,000		66
Castle Creek Biosciences		4,000		72
Divergent Technologies, Inc.		22,500		236
Engage3, LLC		8,000		40
Groundspeed Analytics, Inc.		15,000		150
Hound Labs, Inc.		7,500		88
KSQ Therapeutics, Inc.		10,000		100
Lytics, Inc.		5,000		65
Native Microbials, Inc.		7,500		72
Optoro, Inc.		15,000		38
PDS Biotechnology Corporation		10,000		158
Robin Healthcare, Inc.		10,000		100
Scientia Vascular, Inc.		10,000		110
Slingshot Aerospace, Inc.		5,000		64
Swift Health Systems Inc.		25,500		105
Temperpack Technologies, Inc.		9,000		19
Total	$	190,000	$	1,761

The table above also provides the fair value of the Company’s unfunded commitment liability as of December 31, 2022 which totaled $1.8 million. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

Note 10 - Concentrations of Credit Risk

12 Months Ended

Dec. 31, 2022

Concentration Risk Disclosure [Text Block]

Note 10. Concentrations of credit risk

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The Company’s largest debt investments may vary from year to year as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments, at cost and fair value, represented 23% and 26% of total debt investments outstanding as of December 31, 2022 and 2021, respectively. No single debt investment represented more than 10% of the total debt investments at cost or fair value as of December 31, 2022 or 2021. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments accounted for 15%, 17% and 23% of total interest and fee income on investments for the years ended December 31, 2022, 2021 and 2020, respectively.

Note 11 - Distributions

12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note Disclosure [Text Block]

Note 11. Distributions

The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the years ended December 31, 2022 and 2021:

							*DRIP*		*DRIP*
Date			*Amount*		*Cash*		*Shares*		*Share*
Declared	*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*
			(In thousands, except share and per share data)
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	—		—	$	—
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	29,619		55,095	$	679
Year Ended December 31, 2021
10/22/21	2/18/22	3/16/22	$	0.10	$	2,100		3,409	$	46
10/22/21	1/19/22	2/16/22		0.10		2,096		2,680		43
10/22/21	12/17/21	1/14/22		0.10		2,031		3,417		56
10/22/21	11/18/21	12/15/21		0.05		1,013		1,197		20
7/23/21	11/18/21	12/15/21		0.10		2,027		2,395		38
7/23/21	10/19/21	11/16/21		0.10		2,010		1,907		34
7/23/21	9/17/21	10/15/21		0.10		2,008		2,068		36
4/23/21	8/18/21	9/15/21		0.10		1,996		2,041		34
4/23/21	7/20/21	8/16/21		0.10		1,983		1,937		34
4/23/21	6/17/21	7/16/21		0.10		1,964		1,888		33
2/26/21	5/18/21	6/15/21		0.10		1,964		1,671		29
2/26/21	4/20/21	5/14/21		0.10		1,937		1,794		29
2/26/21	3/18/21	4/16/21		0.10		1,938		1,653		28
			$	1.25	$	25,067		28,057	$	460

On February 23, 2023, the Board declared monthly distributions per share, payable as set forth in the following table:

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
March 16, 2023	March 17, 2023	April 14, 2023	$	0.11
April 17, 2023	April 18, 2023	May 16, 2023	$	0.11
May 17, 2023	May 18, 2023	June 14, 2023	$	0.11

After paying distributions of $1.25 per share deemed paid for tax purposes in 2022, declaring on October 28, 2022 a distribution of $0.11 per share payable January 13, 2023, and taxable earnings of $1.60 per share in 2022, the Company’s undistributed spillover income as of December 31, 2022 was $0.68 per share. Spillover income includes any ordinary income and net capital gains from the preceding tax years that were not distributed during such tax years.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

Note 12 - Subsequent Events

12 Months Ended

Dec. 31, 2022

Subsequent Events [Text Block]

Note 12. Subsequent events

In January 2023, the Company sold 555,654 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $6.6 million, including $0.1 million of offering expenses, from these sales.

On January 24, 2023, pursuant to the terms of an Asset Purchase Agreement dated August 18, 2022 by and between HESP LLC, the Company’s wholly-owned subsidiary (“HESP”) and Cadrenal Therapeutics, Inc. (“CVKD”), HESP received 600,000 shares of common stock of CVKD upon CVKD’s completion of its initial public offering.

On February 1, 2023, Canary Medical Inc. prepaid its outstanding principal balance of $7.5 million on its venture loan, plus interest, end-of-term payment and prepayment fee. The Company continues to hold warrants in Canary Medical Inc.

On February 3, 2023, Unagi Inc. (“Unagi”) prepaid $3.2 million of the outstanding principal of its venture loan. The current outstanding principal balance of the Unagi’s venture loan as of the date hereof is $2.1 million. The Company and Unagi also amended the terms of the venture loan to, among other things, provide for payment in kind (PIK) interest and extend the maturity date of the outstanding principal balance of the loan.

On February 14, 2023, Embody, Inc. prepaid its outstanding principal balance of $2.5 million on its venture loan, plus interest and end-of-term payment.

On February 20, 2023, the Board unanimously approved a new investment advisory agreement with the Advisor, substantially similar to the existing Investment Management Agreement, subject to stockholder approval and the closing of the sale of the Advisor to an affiliate of Monroe Capital LLC (the “Transaction”). The Company does not anticipate the Transaction will substantially or adversely affect the Company. It is anticipated that all of the officers and investment professionals at the Advisor will remain at the Advisor and that the Advisor and the Company will maintain their venture lending-focused investment strategy.

On February 24, 2023, the Company funded a $5.0 million debt investment to an existing portfolio company, BriteCore Holdings, LLC.

On February 24, 2023, the Company funded a $20.0 million debt investment to a new portfolio company, Noodle Partners, Inc.

Note 13 - Financial Highlights

12 Months Ended

Dec. 31, 2022

Investment Company, Financial Highlights [Text Block]

Note 13. Financial highlights

The following table shows financial highlights for the Company:

	*Year ended December 31,*
	*2022*				*2021*				*2020*				*2019*				*2018*
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.56			$	11.02			$	11.83			$	11.64			$	11.72
Net investment income		1.46				1.41				1.18				1.52				1.20
Realized loss (gain)		(0.38	)			(0.18	)			(0.84	)			(0.31	)			0.06
Unrealized (depreciation) appreciation on investments		(0.22	)			0.16				0.02				0.24				(0.13	)
Net increase in net assets resulting from operations		0.86				1.39				0.36				1.45				1.13
Distributions declared ⁽¹⁾		(1.28	)			(1.25	)			(1.25	)			(1.20	)			(1.20	)
From net investment income		(1.28	)			(1.25	)			(1.25	)			(1.20	)			(1.20	)
From net realized gain on investments		—				—				—				—				—
Return of capital		—				—				—				—				—
Other ⁽²⁾		0.33				0.40				0.08				(0.06	)			(0.01	)
Net asset value at end of period	$	11.47			$	11.56			$	11.02			$	11.83			$	11.64
Per share market value, beginning of period	$	15.92			$	13.24			$	12.93			$	11.25			$	11.22
Per share market value, end of period	$	11.60			$	15.92				13.24				12.93				11.25
Total return based on a market value ⁽³⁾		(19.3	)%			29.7	%			12.1	%			25.6	%			11.0	%
Shares outstanding at end of period		27,753,373				21,217,460				19,286,356				15,563,290				11,535,129
Ratios to average net assets:
Expenses without incentive value		11.5	%			10.5	%			10.0	%			10.8	%			10.4	%
Incentive fees		2.6	%			3.1	%			2.6	%			3.2	%			2.4	%
Net expenses		14.1	%			13.6	%			12.6	%			14.0	%			12.8	%
Net investment income with incentive fees		12.1	%			12.2	%			10.4	%			12.8	%			10.3	%
Ratios, without waivers, to average net assets:
Expenses without incentive value ⁽⁴⁾		11.5	%			10.5	%			10.0	%			10.8	%			10.4	%
Incentive fees ⁽⁴⁾		2.6	%			3.1	%			2.6	%			4.4	%			3.3	%
Net expenses ⁽⁴⁾		14.1	%			13.6	%			12.6	%			15.2	%			13.7	%
Net investment income with incentive fees ⁽⁴⁾		12.1	%			12.2	%			10.4	%			11.6	%			9.4	%
Net assets at the end of the period	$	318,448			$	245,335			$	212,597			$	184,055			$	134,257
Average net asset value	$	299,182			$	231,215			$	199,302			$	160,008			$	134,364
Average debt per share	$	13.70			$	11.27			$	9.97			$	10.05			$	8.62
Portfolio turnover ratio		14.6	%	(5)		45.4	%	(5)		38.7	%	(5)		82.0	%	(6)		50.4	%	(6)

(1)

Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.

(2)

Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.

(3)	The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.

(4)	During the years ended December 31, 2019 and 2018, the Advisor waived $1.8 million and $1.2 million, respectively, of incentive fee.

(5)	Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance

(6)	Calculated by dividing net debt investment purchases by the monthly average debt investment balance.

Note 14 - Summarized Financial Information for HSLFI

12 Months Ended

Dec. 31, 2022

Equity Method Investments and Joint Ventures Disclosure [Text Block]

Note 14. Summarized financial information for HSLFI

Horizon Secured Loan Fund I

Statements of Operations

(Dollars in thousands)

	*For the period*
	*January 1, 2020*
	*through*
	*April 21*
	*2021*
Investment income
Interest income	$	1,353
Prepayment fee income		112
Total investment income		1,465
Expenses
Interest expense		1,165
General and administrative		64
Total expenses		1,229
Net investment income		236
Net realized and unrealized loss on investments
Net realized gain on investments		120
Net realized gain on investments		120
Net unrealized depreciation on investments		(392	)
Net unrealized depreciation on investments		(392	)
Net realized and unrealized loss on investments		(272	)
Net decrease in net assets resulting from operations	$	(36	)

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	*Principles of consolidation* As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements. Although the Company owned more than 25% of the voting securities of HSLFI through April 21, 2020, the Company did not have sole control over significant actions of HSLFI for purposes of the 1940 Act or otherwise, and thus did not consolidate its interest prior to April 21, 2020. Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).
Use of Estimates, Policy [Policy Text Block]	*Use of estimates* In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair Value Measurement, Policy [Policy Text Block]	*Fair value* The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date. The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 for additional information regarding fair value.
Segment Reporting, Policy [Policy Text Block]	*Segments* The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investment, Policy [Policy Text Block]	*Investments* Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Company's board of directors (the “Board”) oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff. Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. As of December 31, 2021, there was one investment on non-accrual status with a cost of $11.5 million and a fair value of $6.9 million. For the year ended December 31, 2022, the Company did not recognize any interest income from debt investments on non-accrual status. For the year ended December 31, 2021, the Company recognized, as interest income, payments of $1.3 million received from two portfolio companies whose debt investments were on non-accrual status. For the year ended December 31, 2020, the Company recognized, as interest income, payments of $0.03 million received from one portfolio company whose debt investment was on non-accrual status. The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status. Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the years ended December 31, 2022, 2021 and 2020 was 7.4%, 5.9% and 5.8%, respectively. In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Prior to consolidating the investment in HSLFI on and after April 21, 2020, distributions from HSLFI were evaluated at the time of distribution to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company did not record distributions from HSLFI as dividend income unless there was sufficient accumulated tax-basis earnings and profit in HSLFI prior to distribution. Distributions that were classified as a return of capital were recorded as a reduction in the cost basis of the investment. For the period January 1, 2020 through April 21, 2020, HSLFI made no distributions classified as dividend income or a return of capital to the Company. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
Debt, Policy [Policy Text Block]	*Debt issuance costs* Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of December 31, 2022 and 2021 was $7.1 million and $4.3 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of December 31, 2022 and 2021 were $4.8 million and $3.2 million, respectively. The amortization expense for the years ended December 31, 2022, 2021 and 2020 was $1.6 million, $1.1 million and $1.0 million, respectively.
Income Tax, Policy [Policy Text Block]	*Income taxes* As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the years ended December 31, 2022, 2021 and 2020, the Company reclassified $0.7 million, $0.4 million and $0.2 million, respectively, to paid-in capital from distributions in excess of net investment income, which related to excise taxes payable. Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the years ended December 31, 2022, 2021 and 2020, $0.7 million, $0.4 million and $0.2 million, respectively, was recorded for U.S. federal excise tax. The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at December 31, 2022 and 2021. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.
Distributions [Policy Text Block]	*Distributions* Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment. The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.
Stockholders' Equity, Policy [Policy Text Block]	*Stockholders’ Equity* On August 2, 2019, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2019 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc., (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2019 Equity Distribution Agreement provided that the Company may offer and sell shares of common stock from time to time through the Sales Agents representing up to $50.0 million worth of its common stock, in amounts and at times to be determined by the Company. On July 30, 2020, the Company entered into an ATM sales agreement (the “2020 Equity Distribution Agreement”), with the Sales Agents. The 2020 Equity Distribution Agreement provided that the Company may offer and sell shares of common stock from time to time through the Sales Agents representing up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. On August 2, 2021, the Company terminated the 2020 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2021 Equity Distribution Agreement”) with the Sales Agents. The remaining shares available under the 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement are no longer available for issuance. The 2021 Equity Distribution Agreement provides that the Company may offer and sell our shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of its common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NASDAQ or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. On March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses. During the year ended December 31, 2022, the Company sold 3,982,684 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $50.3 million, including $1.0 million of offering expenses, from these sales. During the year ended December 31, 2021, the Company sold 1,907,234 shares of common stock under the 2021 Equity Distribution Agreement and the 2020 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $30.1 million, including $0.8 million of offering expenses, from these sales. During the year ended December 31, 2020, the Company sold 3,702,500 shares of common stock under the 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $44.6 million, including $1.0 million of offering expenses, from these sales. The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of December 31, 2022, shares representing approximately $31.5 million of its common stock remain available for issuance and sale under the Equity Distribution Agreement.
Stock Repurchase Program [Policy Text Block]	*Stock Repurchase Program* On April 29, 2022, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2023 or the repurchase of $5.0 million of the Company’s common stock. During the years ended December 31, 2022, 2021 and 2020, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through December 31, 2022, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.
Transfers and Servicing of Financial Assets, Policy [Policy Text Block]	*Transfers of financial assets* Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company). Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.
New Accounting Pronouncements, Policy [Policy Text Block]	*Recently adopted accounting pronouncement* In March 2020, the FASB issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. As of December 31, 2022, the Company adopted ASU 2020-04, and such adoption did not have an impact on the Company's consolidated financial statements and disclosures. *Recently issued accounting pronouncement* In June 2022, the FASB issues Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

Consolidated Schedule of Investments (Tables)

12 Months Ended

Dec. 31, 2022

Investment [Table Text Block]

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 226.1% (8)
Non-Affiliate Debt Investments — 215.5% (8)
Non-Affiliate Debt Investments — Life Science — 99.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077
		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630
		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,914		4,914
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,457		2,457
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,463		2,364
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,463		2,364
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,475		2,475
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,489		2,489
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,473		2,473
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,478		2,478
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,478		2,478
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		2,500		2,466		2,466
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		5,000		4,932		4,932
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,898		3,898
		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,898		3,898
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983
Embody, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597
		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349
		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454
Total Non-Affiliate Debt Investments — Life Science																						318,172		317,568
Non-Affiliate Debt Investments — Sustainability — 26.3% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
Total Non-Affiliate Debt Investments — Sustainability																						83,705		83,705
Non-Affiliate Debt Investments — Technology — 81.4% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Convertible Note		3.00	%													July 1, 2023		250		250		306
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977
Better Place Forests Co. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,478		3,478
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,082		1,082
		Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,623		1,623
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,210		3,151		—
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			-		September 1, 2027		2,500		2,588		2,279
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,954		4,954
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,477		2,477
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,943		4,715
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,000		1,981		1,890
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,477		2,363
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		3,000		2,971		2,835
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,914		4,688
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,456		2,342
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,347		2,347
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,967		2,967
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,473		2,473
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
Liqid, Inc. (2)(12)	Networking	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,613		1,613
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,421		2,421
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,487		2,487
Decisyon, Inc. (12)	Software	Term Loan		16.93	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,295		3,295		3,295

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Dropoff, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,347		6,347
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,859		5,859
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,436		2,436
Engage3, LLC (2)(12)	Software	Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,678		3,678
		Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,718		3,718
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,798		4,798
		Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,948		4,948
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,474		2,474
Lytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-			3.00	%	July 1, 2025		2,500		2,396		2,396
		Term Loan		13.00	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,231		1,231
Reputation Institute, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,932		4,932
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,870		4,870
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
Supply Network Visiblity Holdings LLC (2)(12)	Software	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
Total Non-Affiliate Debt Investments — Technology																							268,468		259,366
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,385		2,385
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,473		2,473
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,946		4,946
Secure Transfusion Services, Inc. (2)(12)(13)	Other Healthcare	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,943		4,943		1,668
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,500		2,467		832
BrightInsight, Inc. (2)(12)	Software	Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,619		6,619
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
Total Non-Affiliate Debt Investments — Healthcare information and services																							30,729		25,819
*Total Non- Affiliate Debt Investments*																							701,074		686,458

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 9.4% (8)
Non-Affiliate Warrants — Life Science — 3.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		335
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		263
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		125
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,502		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,077		51		60
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)	Biotechnology	Preferred Stock Warrant		103,679		64		162
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		3,024
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		203,017		399		648
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		14
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		37
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		3
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		64		1,200
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		84		1,864
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		209
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		148		179
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		226
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		150
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		394
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		113

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		385
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		46
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		123
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		83
Total Non-Affiliate Warrants — Life Science						4,197		9,792
Non-Affiliate Warrants — Sustainability — 0.6% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		74
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,539		39		55
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		204,832		488		1,061
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		361
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		35,906		126		268
Total Non-Affiliate Warrants — Sustainability						928		1,819
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		67
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		139		3,265
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		173
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		10,690		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,069
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		20		61
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		125
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		31,966		56		233
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,947
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		—
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		37
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		429
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		534
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		22
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		909
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		442,110		234		407
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		357
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		802
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		243
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,610
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		56		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		69
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		197
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		3
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		6		6
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		296
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		34		41
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		22		312
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		80,197		40		44
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		39
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		46		99
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrants		301,055		48		1
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		133
Supply Network Visiblity Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		83
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		12
Total Non-Affiliate Warrants — Technology						9,249		16,148

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		54
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,370
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		77,690		47		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		80,544		160		170
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		359
Total Non-Affiliate Warrants — Healthcare information and services						416		1,953
*Total Non-Affiliate Warrants*						14,790		29,712
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (2)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
*Total Non-Affiliate Other Investments*						1,200		1,300
Non-Affiliate Equity — 0.8% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		57
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		8		83
Lumithera, Inc. (2)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (2)	Other Sustainability	Preferred		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		108,004		1,079		83
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		—
*Total Non-Affiliate Equity*						4,184		2,556
*Total Non-Affiliate Portfolio Investment Assets*					$	721,248	$	720,026
*Total Portfolio Investment Assets — 226.1% (8)*					$	721,248	$	720,026

Short Term Investments — Unrestricted Investments — 2.2% (8)
US Bank Money Market Deposit Account					$	7,066	$	7,066
*Total Short Term Investments — Unrestricted Investments*					$	7,066	$	7,066

Short Term Investments — Restricted Investments — 0.9% (8)
US Bank Money Market Deposit Account					$	2,788	$	2,788
*Total Short Term Investments — Restricted Investments*					$	2,788	$	2,788

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 186.7% (8)
Non-Affiliate Debt Investments — 178.3% (8)
Non-Affiliate Debt Investments — Life Science — 77.3% (8)
Castle Creek Pharmaceuticals Holdings, Inc. (2)(12)	Biotechnology	Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024	$	5,000	$	4,957	$	4,957
		Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024		5,000		4,957		4,957
		Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024		5,000		4,957		4,957
		Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024		5,000		4,957		4,957
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	January 1, 2025		5,000		4,909		4,909
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	January 1, 2025		5,000		4,909		4,909
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	January 1, 2025		2,500		2,454		2,454
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	February 1, 2025		5,000		4,906		4,906
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	February 1, 2025		5,000		4,906		4,906
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	April 1, 2025		2,500		2,451		2,451
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	April 1, 2025		2,500		2,451		2,451
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		9.75	%	Libor		7.90	%		9.75	%		-		5.00	%	June 1, 2024		2,500		2,420		2,420
		Term Loan		9.75	%	Libor		7.90	%		9.75	%		-		5.00	%	June 1, 2024		2,500		2,472		2,472
		Term Loan		9.75	%	Libor		7.90	%		9.75	%		-		5.00	%	November 1, 2025		5,000		4,896		4,896
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	April 1, 2025		2,500		2,465		2,465
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	July 1, 2025		2,500		2,463		2,463
Greenlight Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	July 1, 2025		5,000		4,850		4,850
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	July 1, 2025		2,500		2,475		2,475
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		9.00	%	Prime		6.25	%		9.00	%		-		5.00	%	July 1, 2025		5,000		4,799		4,799
		Term Loan		9.00	%	Prime		6.25	%		9.00	%		-		5.00	%	July 1, 2025		2,500		2,462		2,462
LogicBio, Inc. (2)(5)(12)	Biotechnology	Term Loan		8.75	%	Libor		6.25	%		8.75	%		-		4.50	%	June 1, 2024		4,028		4,011		4,011
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		5,000		4,935		4,935
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		5,000		4,935		4,935
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,440		2,440
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,440		2,440
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,430		2,430
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,430		2,430
Stealth Biotherapeutics Inc. (2)(5)(12)	Biotechnology	Term Loan		8.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,631		4,631
		Term Loan		8.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,441		2,441
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,394		2,394
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,926		4,926
		Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,957		4,957
		Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,466		2,466
		Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,466		2,466
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		9.25	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		4,056		4,009		4,009
		Term Loan		9.25	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		4,056		4,009		4,009
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		8.50	%	Prime		5.25	%		8.50	%		-		20.00	%	April 1, 2022		2,500		2,495		2,495
		Term Loan		8.50	%	Prime		5.25	%		8.50	%		-		20.00	%	April 1, 2022		2,500		2,495		2,495
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		10.00	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		3,125		3,095		3,095
		Term Loan		10.00	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		208		206		206
		Term Loan		10.00	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		3,600		3,569		3,569

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Embody, Inc. (2)(12)	Medical Device	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,457		2,457
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,500		3,397		3,397
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		963		963
MacuLogix, Inc. (2)(12)(13)	Medical Device	Term Loan		10.08	%	Libor		7.68	%		10.08	%		-		6.00	%	September 1, 2023		7,500		7,447		4,481
		Term Loan		10.08	%	Libor		7.68	%		10.08	%		-		6.00	%	September 1, 2023		4,050		4,022		2,420
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,952		4,952
		Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,952		4,952
		Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,944		4,944
		Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,944		4,944
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		5.00	%	June 1, 2024		2,500		2,391		2,391
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		5.00	%	June 1, 2024		2,500		2,472		2,472
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		5.00	%	June 1, 2024		2,500		2,472		2,472
Spineology, Inc. (2)(12)	Medical Device	Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,928		4,928
Total Non-Affiliate Debt Investments — Life Science																						194,237		189,669
Non-Affiliate Debt Investments — Sustainability — 18.8% (8)
LiquiGlide, Inc. (2)(12)	Other Sustainability	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		5.00	%	January 1, 2025		2,000		1,928		1,928
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,322		7,322
		Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,322		7,322
		Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,322		7,322
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,703		3,703
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,703		3,703
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,396		7,396
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,698		3,698
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,698		3,698
Total Non-Affiliate Debt Investments — Sustainability																						46,092		46,092
Non-Affiliate Debt Investments — Technology — 77.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,442		7,442
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,442		7,442
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,442		7,442
		Convertible Note		3.00	%													July 1, 2023		250		250		250
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,935		4,935
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,949		4,949
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,969		2,969
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		968		968
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,928		4,928
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,430		3,430
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,476		2,476
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,476		2,476
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-		4.00	%	January 1, 2026		6,500		6,397		6,397

Portfolio Company (1)(3)	Sector	Type of Investment (7)	Cash Rate (4)			Index	Margin			Floor			Ceiling			ETP (10)			Maturity Date	Principal Amount		Cost of Investments (6)(9)		Fair Value (9)
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		6,000		5,775		5,775
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			9.75	%	January 1, 2024		2,500		2,480		2,480
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			10.10	%	January 1, 2026		5,000		4,935		4,935
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			10.10	%	January 1, 2026		2,000		1,920		1,920
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		3,000		2,961		2,961
		Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		3,000		2,961		2,961
		Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,955		2,955
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		8.00	%		11.25	%		-			3.00	%	April 1, 2026		10,000		9,639		9,639
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.00	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,446		2,446
		Term Loan		11.00	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,234		1,234
Updater, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.00	%	Prime		5.75	%		12.00	%		14.00	%		0.56	%	December 20, 2024		5,000		4,961		4,961
		Term Loan		12.00	%	Prime		5.75	%		12.00	%		14.00	%		0.56	%	December 20, 2024		5,000		4,961		4,961
		Term Loan		12.00	%	Prime		5.75	%		12.00	%		14.00	%		0.56	%	December 20, 2024		10,000		9,922		9,922
Liqid, Inc. (2)(12)	Networking	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		5,000		4,770		4,770
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		5,000		4,924		4,924
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,500		2,459		2,459
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,500		2,459		2,459
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,500		2,414		2,414
Branded Online, Inc. (2)(12)	Software	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			6.00	%	September 1, 2026		5,000		4,719		4,719
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			6.00	%	November 1, 2026		2,500		2,355		2,355
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			-		July 1, 2023		5,000		5,000		5,000
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			4.00	%	October 1, 2024		2,500		2,481		2,481
		Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			4.00	%	October 1, 2024		2,500		2,481		2,481
Decisyon, Inc. (12)	Software	Term Loan		12.68	%	Prime		9.23	%		12.68	%		-			50.43	%	January 1, 2023		3,470		3,470		3,470
Dropoff, Inc. (2)(12)	Software	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,087		6,087
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,816		5,816
E La Carte, Inc. (2)(12)	Software	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	October 1, 2025		3,000		2,937		2,937
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	October 1, 2025		3,000		2,958		2,958
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	October 1, 2025		1,500		1,479		1,479
Lytics, Inc. (2)(12)	Software	Term Loan		9.25	%	Prime		6.00	%		9.25	%		-			4.00	%	July 1, 2025		2,500		2,464		2,464
Reputation Institute, Inc. (2)(12)	Software	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,905		4,905
Supply Network Visiblity Holdings LLC (2)(12)	Software	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,458		3,458
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,458		3,458
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,463		2,463
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,463		2,463
Total Non-Affiliate Debt Investments — Technology																							189,274		189,274
Non-Affiliate Debt Investments — Healthcare information and services — 5.0% (8)
IDbyDNA, Inc. (2)(12)	Diagnostics	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			5.50	%	January 1, 2025		5,000		4,902		4,902
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			5.50	%	January 1, 2025		5,000		4,936		4,936
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			5.50	%	January 1, 2026		2,500		2,444		2,444
Total Non-Affiliate Debt Investments — Healthcare information and services																							12,282		12,282
*Total Non- Affiliate Debt Investments*																							441,885		437,317

					*Cost of*		Fair
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 8.2% (8)
Non-Affiliate Warrants — Life Science — 1.0% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		317,306		311		27
Castle Creek Pharmaceuticals, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		2,428		142		148
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		54		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		92,002		139		162
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		36		3
Imunon, Inc. (fka Celsion Corporation) (2)(5)(12)	Biotechnology	Common Stock Warrant		295,053		65		1
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		284,090		64		64
LogicBio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		7,843		8		—
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		5
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		164,608		278		519
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		9
Stealth Biotherapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		795,455		264		45
Strongbridge U.S. Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		160,714		72		110
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		463
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,292		53		45
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		134,299		61		172
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		6,361,111		149		169
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		154		108
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		80		90
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		121
MacuLogix, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		454,460		238		—
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		441,780		91		112
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		221,510		83		122
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		484,250		77		75
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		30
Total Non-Affiliate Warrants — Life Science						2,893		2,600
Non-Affiliate Warrants — Sustainability — 0.4% (8)
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,359		39		36
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		142,405		356		331
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		48,756		107		552
Total Non-Affiliate Warrants — Sustainability						502		919

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Technology — 6.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		45		42
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		140		3,141
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		161
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		70
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		1
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		9,353		23		23
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		823
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		22		22
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		368
Getaround, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		651,040		450		367
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		103
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		310,463		47		47
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		51
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		324		503
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		134,421		25		24
Updater, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		31
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		859
Silk, Inc. (2)(12)	Data Storage	Preferred and Common Stock Warrant		44,211,003		234		188
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		6
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		741
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		2,403
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		938
Kinestral, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,609
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrant		6,753		101		—
Branded Online, Inc. (2)(12)	Software	Common Stock Warrant		16,678		370		443
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		55,591		5		37
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		482,283		397		395
E La Carte, Inc. (2)(12)	Software	Preferred Stock Warrant		181,947		61		53
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		23		276
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		26,733		12		12
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		54		52
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		615,475		44		66
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		292
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		224		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrant		301,055		49		4
Supply Network Visiblity Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		62
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		179		1
Total Non-Affiliate Warrants — Technology						6,281		15,214
*Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)*
IDbyDNA, Inc. (2)(12)	Diagnostics	Preferred Stock Warrant		472,006		112		95
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		101		1,177
Watermark Medical, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		27,373		74		—
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		195
Total Non-Affiliate Warrants — Healthcare information and services						347		1,467
*Total Non-Affiliate Warrants*						10,023		20,200
Non-Affiliate Other Investments — 0.1% (8)
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
*Total Non-Affiliate Other Investments*						—		200
Non-Affiliate Equity — 0.1% (8)
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		9		83
Zeta Global Holdings Corp. (2)(5)(12)	Internet and Media	Common Stock		18,405		240		155
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		120
*Total Non-Affiliate Equity*						479		358
*Total Non-Affiliate Portfolio Investment Assets*					$	452,387	$	458,075
Controlled Affiliate Investments — 0.0% (8)
*Controlled Affiliate Other Investments — Biotechnology — 0.0% (8)*
HESP LLC (12)(14)	Biotechnology	Other Investment			$	1,450	$	—
*Total Controlled Affiliate Other Investments*						1,450		—
*Total Controlled Affiliate Portfolio Investment Assets*					$	1,450	$	—
*Total Portfolio Investment Assets — 186.7% (8)*					$	453,837	$	458,075

Short Term Investments — Unrestricted Investments — 3.2% (8)
US Bank Money Market Deposit Account					$	7,868	$	7,868
*Total Short Term Investments — Unrestricted Investments*					$	7,868	$	7,868

Short Term Investments — Restricted Investments — 0.6% (8)
US Bank Money Market Deposit Account					$	1,359	$	1,359
*Total Short Term Investments — Restricted Investments*					$	1,359	$	1,359

Note 4 - Investments (Tables)

12 Months Ended

Dec. 31, 2022

Investment Holdings, Schedule of Investments [Table Text Block]

	*December 31, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Investments
Debt	$	701,074	$	686,458	$	441,885	$	437,317
Warrants		14,790		29,712		10,023		20,200
Other		1,200		1,300		1,450		200
Equity		4,184		2,556		479		358
Total investments	$	721,248	$	720,026	$	453,837	$	458,075

	*December 31, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Life Science
Biotechnology	$	193,372	$	195,006	$	109,899	$	107,902
Medical Device		132,803		135,960		88,681		84,567
Technology
Communications		22,892		26,176		22,853		25,920
Consumer-Related		121,961		114,050		92,158		93,194
Data Storage		476		1,316		476		1,047
Internet and Media		329		1,159		569		3,305
Networking		11,831		11,710		17,390		17,964
Power Management		1,585		2,610		1,585		2,609
Semiconductors		56		—		101		—
Software		120,157		118,716		60,902		60,807
Sustainability
Energy Efficiency		8		27		—		—
Other Sustainability		84,633		85,524		46,595		47,011
Healthcare Information and Services
Diagnostics		9,851		9,858		12,393		12,377
Other		7,559		3,870		175		1,177
Software		13,735		14,044		60		195
Total investments	$	721,248	$	720,026	$	453,837	$	458,075

Selected Statement of Operations for Nonconsolidated Investment [Table Text Block]

	For the period
	January 1, 2020
	through
	April 21, 2020
	(In thousands)
Selected Statements of Operations Information
Interest income on investments	$	1,353
Total investment income	$	1,465
Total expenses	$	1,229
Net investment income	$	236
Net realized gain on investments	$	120
Net unrealized depreciation on investments	$	(392	)
Net decrease in net assets resulting from operations	$	(36	)

Note 5 - Transactions With Affiliated Companies (Tables)

12 Months Ended

Dec. 31, 2022

Investments in and Advances to Affiliates [Table Text Block]

					Year ended December 31, 2021
	*Fair value at*							*Transfers*					*Net*						*Fair value at*
Portfolio	*December 31,*				*Principal*			*in/(out) at*			*Discount*		*unrealized*			*Net realized*			*December 31,*		*Interest*
Company	*2020*		*Purchases*		*Payments*			*fair value*			*accretion*		*gain/(loss)*			*gain/(loss)*			*2021*		*income*
	(In thousands)
Decisyon, Inc. ⁽¹⁾	$	1,181	$	—	$	—		$	(1,181	)	$	—	$	—		$	—		$	—	$	41
		626		—		—			(638	)		12		—			—			—		21
		227		—		—			(227	)		—		—			—			—		7
		228		—		—			(228	)		—		—			—			—		7
		685		—		—			(685	)		—		—			—			—		22
		276		—		—			(276	)		—		—			—			—		9
		183		—		—			(183	)		—		—			—			—		6
		120		—		—			(120	)		—		—			—			—		—
MVI (ABC) LLC fka StereoVision, Inc.		2,382		—		(2,783	)		—			—		—			401			—		139
		—		250		(250	)		—			—		—			—			—		—
		—		70		(70	)		—			—		—			—			—		—
		—		330		(330	)		—			—		—						—		—
		—		150		(150	)		—			—		—			—			—		—
		1,639		—		—			—			—		(848	)		(791	)		—		—
Total non-controlled affiliates	$	7,547	$	800	$	(3,583	)	$	(3,538	)	$	12	$	(848	)	$	(390	)	$	—	$	252

					*Year ended December 31, 2022*

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*		*Net realized*			*December 31,*		*Dividend*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*		*gain/(loss)*			*2022*		*income*
	(In thousands)
HESP LLC		—		—		(300	)		—		—		1,450		(1,150	)		—		—
Total controlled affiliates	$	—	$	—	$	(300	)	$	—	$	—	$	1,450	$	(1,150	)	$	—	$	—

					Year ended December 31, 2021

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*			*Net realized*		*December 31,*		*Dividend*
Company	*2020*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*			*gain/(loss)*		*2021*		*income*
	(In thousands)
HESP LLC		1,500		—		(50	)		—		—		(1,450	)		—		—		—
Total controlled affiliates	$	1,500	$	—	$	(50	)	$	—	$	—	$	(1,450	)	$	—	$	—	$	—

Note 6 - Fair Value (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

*December 31, 2022*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*
			(Dollars in thousands, except per share data)
Debt investments	$	669,617	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 22%		14	%

		16,545	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 75%		31	%

		296	Convertible Note Analysis	Price Per Share	$168.93	$	168.93

Warrant investments		26,145	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	58.52
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3

Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%

Equity investments		2,416	Last Equity Financing	Price Per Share	$1.00– $215.03	$	26.93

Total Level 3 investments	$	716,319

December 31, 2021
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average⁽¹⁾
			(Dollars in thousands, except per share data)
Debt investments	$	430,417	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 23%		12	%

		6,900	Multiple Probability Weighted Cash Flow Model	Probability Weighting	20% - 50%		33	%

Warrant investments		19,837	Black-Scholes Valuation Model	Price Per Share	0.000 –980.0000	$	20.35
				Average Industry Volatility	25%		25	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 4		2

Other investments		200	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	0% – 100%		100	%

Equity investments		203	Last Equity Financing	Price Per Share	0.000 –1.0000	$	0.41

Total Level 3 investments	$	457,557

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	*December 31, 2022*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Investments in money market funds	$	—	$	7,066	$	—	$	7,066
Restricted investments in money market funds	$	—	$	2,788	$	—	$	2,788
Debt investments	$	—	$	—	$	686,458	$	686,458
Warrant investments		—		3,567		26,145		29,712
Other investments		—		—		1,300		1,300
Equity investments		140		—		2,416		2,556
Total investments	$	140	$	3,567	$	716,319	$	720,026

	December 31, 2021
	Level 1		Level 2		Level 3		Total
	(In thousands)
Investments in money market funds	$	—	$	7,868	$	—	$	7,868
Restricted investments in money market funds	$	—	$	1,359	$	—	$	1,359
Debt investments	$	—	$	—	$	437,317	$	437,317
Warrant investments		—		363		19,837		20,200
Other investments		—		—		200		200
Equity investments		155		—		203		358
Total investments	$	155	$	363	$	457,557	$	458,075

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	*Year ended December 31, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203		$	200		$	457,557
Purchase of investments		421,372			—			606			—			421,978
Warrants and equity received and classified as Level 3		—			5,664			8			—			5,672
Principal payments received on investments		(95,558	)		—			—			(313	)		(95,871	)
Proceeds from sale of investments		(49,371	)		(464	)		—			—			(49,835	)
Net realized (loss) gain on investments		(8,221	)		264			—			(1,137	)		(9,094	)
Unrealized (depreciation) appreciation included in earnings		(10,044	)		2,215			(401	)		1,350			(6,880	)
Transfer out of Level 3		—			(1,371	)		—						(1,371	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(5,837	)		—			—			—			(5,837	)
Level 3 assets, end of period	$	686,458		$	26,145		$	2,416		$	1,300		$	716,319

	*Year ended December 31, 2021*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	333,495		$	12,736		$	2,117		$	1,700		$	350,048
Purchase of investments		344,445			—			—			—			344,445
Warrants and equity received and classified as Level 3		—			2,681			—			—			2,681
Principal payments received on investments		(188,010	)		—			—			—			(188,010	)
Proceeds from sale of investments		(47,436	)		(3,241	)		—			(13	)		(50,690	)
Net realized (loss) gain on investments		(5,033	)		2,514			—			—			(2,519	)
Unrealized appreciation (depreciation) included in earnings		1,836			5,218			(1,682	)		(1,487	)		3,885
Transfer out of Level 3		—			(71	)		(232	)		—			(303	)
Other		(1,980	)		—			—			—			(1,980	)
Level 3 assets, end of period	$	437,317		$	19,837		$	203		$	200		$	457,557

Note 7 - Borrowings (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of Debt [Table Text Block]

	*December 31, 2022*							*December 31, 2021*
	*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*
	*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*
	(In thousands)
Key Facility	$	125,000	$	5,000		$	120,000	$	125,000	$	53,500		$	71,500
NYL Facility		200,000		176,750			23,250		100,000		78,750			21,250
2019 Asset-Backed Notes		42,573		42,573			—		70,500		70,500			—
2022 Asset-Backed Notes		100,000		100,000			—		—		—			—
2027 Notes		57,500		57,500			—		—		—			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		582,573		439,323			143,250		353,000		260,250			92,750
Unamortized debt issuance costs attributable to term borrowings		—		(5,245	)		—		—		(2,637	)		—
Total borrowings outstanding, net	$	582,573	$	434,078		$	143,250	$	353,000	$	257,613		$	92,750

Schedule of Long-Term Debt Instruments [Table Text Block]

	*Total Amount*
	*Outstanding*				*Involuntary*		*Average*
	*Exclusive of*		*Asset*		*Liquidation*		*Market*
	*Treasury*		*Coverage*		*Preference*		*Value per*
Class and Year	*Securities(1)*		*per Unit(2)*		*per Unit(3)*		*Unit(4)*
	(In thousands, except unit data)
Credit facilities
2022	$	181,750	$	4,169		—		N/A
2021	$	132,250	$	3,823		—		N/A
2020	$	50,250	$	7,965		—		N/A
2019	$	17,000	$	19,908		—		N/A
2018	$	90,500	$	2,896		—		N/A
2027 Notes
2022	$	57,500	$	13,179		—	$	24.09
2026 Notes
2022	$	57,500	$	13,179		—	$	24.45
2021	$	57,500	$	8,793		—	$	25.90
2022 Notes
2022	$	—	$	—		—		N/A
2021	$	—	$	—		—		N/A
2020	$	37,375	$	10,708		—	$	24.60
2019	$	37,375	$	9,055		—	$	25.53
2017	$	37,375	$	7,014			$	25.52
2022-1 Securitization
2022	$	100,000	$	7,578		—		N/A
2019-1 Securitization
2022	$	42,573	$	17,799		—		N/A
2021	$	70,500	$	7,171		—		N/A
2020	$	100,000	$	4,002		—		N/A
2019	$	100,000	$	3,384		—		N/A
Total senior securities
2022	$	439,323	$	1,725		—		N/A
2021	$	260,250	$	1,943		—		N/A
2020	$	187,625	$	2,133		—		N/A
2019	$	154,375	$	2,192		—		N/A
2018	$	127,875	$	2,050		—		N/A

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

Note 8 - Federal Income Tax (Tables)

12 Months Ended

Dec. 31, 2022

Federal Income Tax Note [Table Text Block]

	*Years Ended December 31,*
	*2022*		*2021*			*2020*
	(In thousands)
Net increase in net assets resulting from operations	$	21,151	$	27,782		$	6,364
Net unrealized depreciation (appreciation) on investments		5,552		(3,205	)		(313	)
Other book-tax differences		3,292		1,462			782
Change in capital loss carry forward		9,484		3,643			14,698
Taxable income before deductions for distributions	$	39,479	$	29,682		$	21,531

Schedule of Tax Characters of Distribution Paid [Table Text Block]

	*Years Ended December 31,*
	*2022*		*2021*		*2020*
	(In thousands)
Ordinary income	$	31,490	$	25,099	$	21,592
Total	$	31,490	$	25,099	$	21,592

Schedule of Investment Company, Distributable Earnings (Loss) [Table Text Block]

	*As of December 31,*
	*2022*			*2021*			*2020*
	(In thousands)
Undistributed ordinary income	$	18,813		$	10,825		$	6,242
Long term capital loss carry forward		(73,055	)		(63,571	)		(59,928	)
Unrealized appreciation		18,542			12,973			9,578
Unrealized depreciation		(19,771	)		(8,738	)		(8,545	)
Other temporary differences		11,875			7,465			5,983
Total	$	(43,596	)	$	(41,046	)	$	(46,670	)

Note 9 - Financial Instruments With Off-balance-sheet Risk (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]

	*December 31, 2022*
			*Fair Value of*
			*Unfunded*
	*Principal*		*Commitment*
	*Balance*		*Liability*
	(In thousands)
BrightInsight, Inc.	$	21,000	$	278
Britecore Holdings, Inc.		5,000		66
Castle Creek Biosciences		4,000		72
Divergent Technologies, Inc.		22,500		236
Engage3, LLC		8,000		40
Groundspeed Analytics, Inc.		15,000		150
Hound Labs, Inc.		7,500		88
KSQ Therapeutics, Inc.		10,000		100
Lytics, Inc.		5,000		65
Native Microbials, Inc.		7,500		72
Optoro, Inc.		15,000		38
PDS Biotechnology Corporation		10,000		158
Robin Healthcare, Inc.		10,000		100
Scientia Vascular, Inc.		10,000		110
Slingshot Aerospace, Inc.		5,000		64
Swift Health Systems Inc.		25,500		105
Temperpack Technologies, Inc.		9,000		19
Total	$	190,000	$	1,761

Note 11 - Distributions (Tables)

12 Months Ended

Dec. 31, 2022

Dividends Declared [Table Text Block]

							*DRIP*		*DRIP*
Date			*Amount*		*Cash*		*Shares*		*Share*
Declared	*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*
			(In thousands, except share and per share data)
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	—		—	$	—
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	29,619		55,095	$	679
Year Ended December 31, 2021
10/22/21	2/18/22	3/16/22	$	0.10	$	2,100		3,409	$	46
10/22/21	1/19/22	2/16/22		0.10		2,096		2,680		43
10/22/21	12/17/21	1/14/22		0.10		2,031		3,417		56
10/22/21	11/18/21	12/15/21		0.05		1,013		1,197		20
7/23/21	11/18/21	12/15/21		0.10		2,027		2,395		38
7/23/21	10/19/21	11/16/21		0.10		2,010		1,907		34
7/23/21	9/17/21	10/15/21		0.10		2,008		2,068		36
4/23/21	8/18/21	9/15/21		0.10		1,996		2,041		34
4/23/21	7/20/21	8/16/21		0.10		1,983		1,937		34
4/23/21	6/17/21	7/16/21		0.10		1,964		1,888		33
2/26/21	5/18/21	6/15/21		0.10		1,964		1,671		29
2/26/21	4/20/21	5/14/21		0.10		1,937		1,794		29
2/26/21	3/18/21	4/16/21		0.10		1,938		1,653		28
			$	1.25	$	25,067		28,057	$	460

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
March 16, 2023	March 17, 2023	April 14, 2023	$	0.11
April 17, 2023	April 18, 2023	May 16, 2023	$	0.11
May 17, 2023	May 18, 2023	June 14, 2023	$	0.11

Note 13 - Financial Highlights (Tables)

12 Months Ended

Dec. 31, 2022

Investment Company, Financial Highlights [Table Text Block]

	*Year ended December 31,*
	*2022*				*2021*				*2020*				*2019*				*2018*
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.56			$	11.02			$	11.83			$	11.64			$	11.72
Net investment income		1.46				1.41				1.18				1.52				1.20
Realized loss (gain)		(0.38	)			(0.18	)			(0.84	)			(0.31	)			0.06
Unrealized (depreciation) appreciation on investments		(0.22	)			0.16				0.02				0.24				(0.13	)
Net increase in net assets resulting from operations		0.86				1.39				0.36				1.45				1.13
Distributions declared ⁽¹⁾		(1.28	)			(1.25	)			(1.25	)			(1.20	)			(1.20	)
From net investment income		(1.28	)			(1.25	)			(1.25	)			(1.20	)			(1.20	)
From net realized gain on investments		—				—				—				—				—
Return of capital		—				—				—				—				—
Other ⁽²⁾		0.33				0.40				0.08				(0.06	)			(0.01	)
Net asset value at end of period	$	11.47			$	11.56			$	11.02			$	11.83			$	11.64
Per share market value, beginning of period	$	15.92			$	13.24			$	12.93			$	11.25			$	11.22
Per share market value, end of period	$	11.60			$	15.92				13.24				12.93				11.25
Total return based on a market value ⁽³⁾		(19.3	)%			29.7	%			12.1	%			25.6	%			11.0	%
Shares outstanding at end of period		27,753,373				21,217,460				19,286,356				15,563,290				11,535,129
Ratios to average net assets:
Expenses without incentive value		11.5	%			10.5	%			10.0	%			10.8	%			10.4	%
Incentive fees		2.6	%			3.1	%			2.6	%			3.2	%			2.4	%
Net expenses		14.1	%			13.6	%			12.6	%			14.0	%			12.8	%
Net investment income with incentive fees		12.1	%			12.2	%			10.4	%			12.8	%			10.3	%
Ratios, without waivers, to average net assets:
Expenses without incentive value ⁽⁴⁾		11.5	%			10.5	%			10.0	%			10.8	%			10.4	%
Incentive fees ⁽⁴⁾		2.6	%			3.1	%			2.6	%			4.4	%			3.3	%
Net expenses ⁽⁴⁾		14.1	%			13.6	%			12.6	%			15.2	%			13.7	%
Net investment income with incentive fees ⁽⁴⁾		12.1	%			12.2	%			10.4	%			11.6	%			9.4	%
Net assets at the end of the period	$	318,448			$	245,335			$	212,597			$	184,055			$	134,257
Average net asset value	$	299,182			$	231,215			$	199,302			$	160,008			$	134,364
Average debt per share	$	13.70			$	11.27			$	9.97			$	10.05			$	8.62
Portfolio turnover ratio		14.6	%	(5)		45.4	%	(5)		38.7	%	(5)		82.0	%	(6)		50.4	%	(6)

Note 14 - Summarized Financial Information for HSLFI (Tables)

12 Months Ended

Dec. 31, 2022

Equity Method Investments [Table Text Block]

	*For the period*
	*January 1, 2020*
	*through*
	*April 21*
	*2021*
Investment income
Interest income	$	1,353
Prepayment fee income		112
Total investment income		1,465
Expenses
Interest expense		1,165
General and administrative		64
Total expenses		1,229
Net investment income		236
Net realized and unrealized loss on investments
Net realized gain on investments		120
Net realized gain on investments		120
Net unrealized depreciation on investments		(392	)
Net unrealized depreciation on investments		(392	)
Net realized and unrealized loss on investments		(272	)
Net decrease in net assets resulting from operations	$	(36	)

Consolidated Schedule of Investments (Details Textual) - USD ($) $ in Thousands	Oct. 22, 2020	Dec. 31, 2022	Nov. 09, 2022	Dec. 31, 2021	Aug. 13, 2019
Debt Instrument, Face Amount		$ 582,573		$ 353,000
Percentage of Nonqualifying Assets on a Cost Basis		6.50%		5.80%
Percentage of Nonqualifying Assets on a Fair Value Basis		6.60%		5.80%
Assets of Espero [Member]
Asset Acquisition, Consideration Transferred, Total	$ 7,000
Asset-backed Notes 2019 [Member]
Debt Instrument, Face Amount					$ 160,000
Asset-backed Notes 2019 [Member] \| Affiliated Entity [Member]
Debt Instrument, Face Amount					$ 100,000
Asset-backed Notes 2022 [Member]
Debt Instrument, Face Amount		$ 100,000	$ 157,800	$ 0
Asset-backed Notes 2022 [Member] \| Affiliated Entity [Member]
Debt Instrument, Face Amount			$ 100,000

Consolidated Schedule of Investments - Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Investments at cost	$ 721,248	$ 453,837
Investments at fair value	$ 720,026	$ 458,075
NAV %	226.10%	186.70%
Money Market Funds, Unrestricted Investment [Member]
Investments at cost	$ 7,066	$ 7,868
Investments at fair value	7,066	7,868
Unrestricted Short Term Investments [Member]
Investments at cost	7,066	7,868
Investments at fair value	$ 7,066	$ 7,868
NAV %	2.20%	3.20%
Money Market Funds, Restricted Investments [Member]
Investments at cost	$ 2,788	$ 1,359
Investments at fair value	2,788	1,359
Restricted Short Term Investments [Member]
Investments at cost	2,788	1,359
Investments at fair value	$ 2,788	$ 1,359
NAV %	0.90%	0.60%
Non-affiliate [Member]
Investments at cost	$ 721,248	$ 452,387
Investments at fair value	$ 720,026	$ 458,075
NAV %	226.10%	186.70%
Non-affiliate [Member] \| Warrant [Member]
Investments at cost	$ 14,790	$ 10,023
Investments at fair value	$ 29,712	$ 20,200
NAV %	9.40%	8.20%
Non-affiliate [Member] \| Debt Investments [Member]
Investments at cost	$ 701,074	$ 441,885
Investments at fair value	$ 686,458	$ 437,317
NAV %	215.50%	178.30%
Non-affiliate [Member] \| Other Long-Term Investments [Member]
Investments at cost	$ 1,200	$ 0
Investments at fair value	$ 1,300	$ 200
NAV %	0.40%	0.10%
Non-affiliate [Member] \| Preferred and Common Stock [Member]
Investments at cost		$ 479
Investments at fair value		$ 358
Non-affiliate [Member] \| Equity Securities [Member]
Investments at cost	$ 4,184
Investments at fair value	$ 2,556
NAV %	0.80%	0.10%
Controlled Affiliate [Member]
Investments at cost		$ 1,450
Investments at fair value		$ 0
NAV %		0.00%
Controlled Affiliate [Member] \| Other Long-Term Investments [Member]
Investments at cost		$ 1,450
Investments at fair value		$ 0
Consumer-related Technologies [Member] \| Interior Define, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 2,963	$ 6,000
Investments at cost	2,886	5,775
Investments at fair value	$ 0	$ 5,775
Consumer-related Technologies [Member] \| Interior Define, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 3,210	$ 6,500
Investments at cost	3,151	6,397
Investments at fair value	0	6,397
Consumer-related Technologies [Member] \| Interior Define, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	103	103
Investments at fair value	$ 0	$ 103
Number of Shares (in shares)	553,710	553,710
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,238
Investments at fair value	$ 1,238
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,478
Investments at fair value	3,478
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	56
Investments at fair value	$ 233
Number of Shares (in shares)	31,966
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,715
Investments at fair value	$ 3,715
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,238
Investments at fair value	$ 1,238
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,715
Investments at fair value	$ 3,715
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index, Six [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,238
Investments at fair value	$ 1,238
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index, Seven [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 3,750
Investments at cost	3,698
Investments at fair value	$ 3,698
Consumer-related Technologies [Member] \| Divergent Technologies, Inc. [Member] \| Term Loan, Prime Index, Eight [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 3,750
Investments at cost	3,698
Investments at fair value	$ 3,698
Consumer-related Technologies [Member] \| Lyrical Foods, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	10.00%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	0.00%	9.75%
Maturity Date	Sep. 01, 2027	Jan. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,588	2,480
Investments at fair value	$ 2,279	$ 2,480
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	9.00%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling Rate	0.00%	0.00%
ETP	2.00%	10.10%
Maturity Date	Dec. 30, 2022	Jan. 01, 2026
Principal Amount	$ 2,000	$ 2,000
Investments at cost	1,981	1,920
Investments at fair value	$ 1,890	$ 1,920
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	9.00%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling Rate	0.00%	0.00%
ETP	2.00%	10.10%
Maturity Date	Dec. 30, 2022	Jan. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,943	4,935
Investments at fair value	4,715	4,935
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	197	47
Investments at fair value	$ 17	$ 47
Number of Shares (in shares)	1,261,253	310,463
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,477
Investments at fair value	$ 2,363
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 3,000
Investments at cost	2,971
Investments at fair value	$ 2,835
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,459
Investments at fair value	$ 2,345
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index, Six [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,459
Investments at fair value	$ 2,345
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index, Eight [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 5,000
Investments at cost	4,914
Investments at fair value	$ 4,688
Consumer-related Technologies [Member] \| NextCar Holding Company, Inc [Member] \| Term Loan, Prime Index, Nine [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,456
Investments at fair value	2,342
Consumer-related Technologies [Member] \| Aerofarms, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	61
Investments at fair value	$ 74
Number of Shares (in shares)	201,537
Consumer-related Technologies [Member] \| Primary Kids, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,700	$ 3,000
Investments at cost	2,673	2,961
Investments at fair value	$ 2,673	$ 2,961
Consumer-related Technologies [Member] \| Primary Kids, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,700	$ 3,000
Investments at cost	2,673	2,961
Investments at fair value	2,673	2,961
Consumer-related Technologies [Member] \| Primary Kids, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	57	57
Investments at fair value	$ 429	$ 51
Number of Shares (in shares)	553,778	553,778
Consumer-related Technologies [Member] \| Primary Kids, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,967	2,955
Investments at fair value	$ 2,967	$ 2,955
Consumer-related Technologies [Member] \| Alula Holdings, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,966	4,949
Investments at fair value	$ 4,966	$ 4,949
Consumer-related Technologies [Member] \| Alula Holdings, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,966	4,935
Investments at fair value	4,966	4,935
Consumer-related Technologies [Member] \| Alula Holdings, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	93	93
Investments at fair value	$ 64	$ 70
Number of Shares (in shares)	20,000	20,000
Consumer-related Technologies [Member] \| Alula Holdings, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,979	2,969
Investments at fair value	$ 2,979	$ 2,969
Consumer-related Technologies [Member] \| Alula Holdings, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 1,000	$ 1,000
Investments at cost	976	968
Investments at fair value	$ 976	968
Consumer-related Technologies [Member] \| Alula Holdings, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	13.75%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Feb. 01, 2026
Principal Amount	$ 1,000
Investments at cost	977
Investments at fair value	977
Consumer-related Technologies [Member] \| Aterian, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	195	195
Investments at fair value	$ 0	$ 1
Number of Shares (in shares)	76,923	76,923
Consumer-related Technologies [Member] \| Quip NYC Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate		11.25%
Margin		8.00%
Floor		11.25%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 10,000
Investments at cost		9,639
Investments at fair value		9,639
Consumer-related Technologies [Member] \| Quip NYC Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 325	324
Investments at fair value	$ 534	$ 503
Number of Shares (in shares)	6,191	6,191
Consumer-related Technologies [Member] \| Better Place Forests Co. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	1.85%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 1,916
Consumer-related Technologies [Member] \| Better Place Forests Co. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	1.85%	1.85%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,928
Investments at fair value	3,834	4,928
Consumer-related Technologies [Member] \| Better Place Forests Co. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	26	23
Investments at fair value	$ 0	$ 23
Number of Shares (in shares)	10,690	9,353
Consumer-related Technologies [Member] \| Unagi, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	15.25%	11.00%
Margin	7.75%	7.75%
Floor	11.00%	11.00%
Ceiling Rate	0.00%	0.00%
ETP	0.00%	0.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,236	1,234
Investments at fair value	$ 1,236	$ 1,234
Consumer-related Technologies [Member] \| Unagi, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	15.25%	11.00%
Margin	7.75%	7.75%
Floor	11.00%	11.00%
Ceiling Rate	0.00%	0.00%
ETP	0.00%	0.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,473	2,446
Investments at fair value	2,473	2,446
Consumer-related Technologies [Member] \| Unagi, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	32	25
Investments at fair value	$ 22	$ 24
Number of Shares (in shares)	171,081	134,421
Consumer-related Technologies [Member] \| Unagi, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	15.25%
Margin	7.75%
Floor	11.00%
Ceiling Rate	0.00%
ETP	0.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 1,250
Investments at cost	1,236
Investments at fair value	1,236
Consumer-related Technologies [Member] \| Caastle, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	68	$ 68
Investments at fair value	$ 1,069	$ 823
Number of Shares (in shares)	268,591	268,591
Consumer-related Technologies [Member] \| Havenly, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.50%
Margin	5.00%
Floor	5.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 3,000
Investments at cost	1,623
Investments at fair value	$ 1,623
Consumer-related Technologies [Member] \| Havenly, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.50%
Margin	5.00%
Floor	5.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 2,000
Investments at cost	1,082
Investments at fair value	1,082
Consumer-related Technologies [Member] \| Havenly, Inc. [Member] \| Common Stock Warrants [Member]
Investments at cost	2,947
Investments at fair value	$ 2,947
Number of Shares (in shares)	1,312,500
Consumer-related Technologies [Member] \| Havenly, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	11.00%
Margin	3.50%
Floor	10.50%
Ceiling Rate	0.00%
ETP	7.78%
Maturity Date	Feb. 01, 2028
Principal Amount	$ 2,813
Investments at cost	2,813
Investments at fair value	$ 2,813
Consumer-related Technologies [Member] \| Havenly, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	11.00%
Margin	3.50%
Floor	10.50%
Ceiling Rate	0.00%
ETP	7.78%
Maturity Date	Feb. 01, 2028
Principal Amount	$ 2,813
Investments at cost	2,813
Investments at fair value	$ 2,813
Consumer-related Technologies [Member] \| CAMP NYC, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,461	3,430
Investments at fair value	3,461	3,430
Consumer-related Technologies [Member] \| CAMP NYC, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	20	22
Investments at fair value	$ 61	$ 22
Number of Shares (in shares)	17,605	17,605
Consumer-related Technologies [Member] \| Updater, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate		12.00%
Margin		5.75%
Floor		12.00%
Ceiling Rate		14.00%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		$ 4,961
Consumer-related Technologies [Member] \| Updater, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate		12.00%
Margin		5.75%
Floor		12.00%
Ceiling Rate		14.00%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		4,961
Consumer-related Technologies [Member] \| Updater, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	$ 34	34
Investments at fair value	$ 42	$ 31
Number of Shares (in shares)	108,333	108,333
Consumer-related Technologies [Member] \| Updater, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate		12.00%
Margin		5.75%
Floor		12.00%
Ceiling Rate		14.00%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 10,000
Investments at cost		9,922
Investments at fair value		$ 9,922
Consumer-related Technologies [Member] \| Clara Foods Co [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	9.00%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,482	2,476
Investments at fair value	$ 2,482	$ 2,476
Consumer-related Technologies [Member] \| Clara Foods Co [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	9.00%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,482	2,476
Investments at fair value	2,482	2,476
Consumer-related Technologies [Member] \| Clara Foods Co [Member] \| Preferred Stock Warrants [Member]
Investments at cost	30	30
Investments at fair value	$ 125	$ 368
Number of Shares (in shares)	46,745	46,745
Consumer-related Technologies [Member] \| Getaround, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost		$ 450
Investments at fair value		$ 367
Number of Shares (in shares)		651,040
Consumer-related Technologies [Member] \| SnagAJob.com, Inc [Member] \| Common Stock [Member]
Investments at cost	$ 8	$ 9
Investments at fair value	$ 83	$ 83
Number of Shares (in shares)	82,974	82,974
Consumer-related Technologies [Member] \| MyForest Foods Co [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,477
Investments at fair value	$ 2,477
Consumer-related Technologies [Member] \| MyForest Foods Co [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,954
Investments at fair value	4,954
Consumer-related Technologies [Member] \| MyForest Foods Co [Member] \| Preferred Stock Warrants [Member]
Investments at cost	29
Investments at fair value	$ 37
Number of Shares (in shares)	143
Consumer-related Technologies [Member] \| Optoro, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,347
Investments at fair value	2,347
Consumer-related Technologies [Member] \| Optoro, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	104
Investments at fair value	$ 104
Number of Shares (in shares)	6,600
Biotechnology Sector [Member]
Investments at cost	$ 193,372	$ 109,899
Investments at fair value	$ 195,006	$ 107,902
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,823	4,909
Investments at fair value	$ 2,750	$ 4,909
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,853	4,909
Investments at fair value	2,777	4,909
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Common Stock Warrants [Member]
Investments at cost	311	311
Investments at fair value	$ 0	$ 27
Number of Shares (in shares)	26,442	317,306
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 1,442	$ 2,500
Investments at cost	1,411	2,454
Investments at fair value	$ 1,374	$ 2,454
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,821	4,906
Investments at fair value	$ 2,748	$ 4,906
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	13.75%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,821	4,906
Investments at fair value	$ 2,748	$ 4,906
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Term Loan, Prime Index, Six [Member]
Cash Rate	13.75%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 2,500
Investments at cost	1,408	2,451
Investments at fair value	$ 1,371	$ 2,451
Biotechnology Sector [Member] \| Avalo Therapeutics, Inc. [Member] \| Term Loan, Prime Index, Seven [Member]
Cash Rate	13.75%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 2,500
Investments at cost	1,408	2,451
Investments at fair value	$ 1,371	$ 2,451
Biotechnology Sector [Member] \| Stealth BioTherapeutics Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.00%	8.75%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling Rate	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,457	2,441
Investments at fair value	$ 2,457	$ 2,441
Biotechnology Sector [Member] \| Stealth BioTherapeutics Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.00%	8.75%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling Rate	0.00%	0.00%
ETP	6.00%	6.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,914	4,631
Investments at fair value	4,914	4,631
Biotechnology Sector [Member] \| Stealth BioTherapeutics Inc. [Member] \| Common Stock Warrants [Member]
Investments at cost	264	264
Investments at fair value	$ 37	$ 45
Number of Shares (in shares)	318,181	795,455
Biotechnology Sector [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member] \| Term Loan, LIBOR Index, Three [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member] \| Term Loan, LIBOR Index, Four [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		4,957
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member]
Cash Rate	12.50%
Margin	605.00%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.50%
Margin	605.00%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,978
Investments at fair value	$ 2,978
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.50%
Margin	605.00%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,891
Investments at fair value	4,891
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	214	142
Investments at fair value	$ 335	$ 148
Number of Shares (in shares)	7,404	2,428
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	12.50%
Margin	605.00%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	12.50%
Margin	605.00%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	12.50%
Margin	605.00%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,978
Investments at fair value	2,978
Biotechnology Sector [Member] \| Castle Creek Biosciences, Inc [Member] \| Common Stock [Member]
Investments at cost	250
Investments at fair value	$ 250
Number of Shares (in shares)	1,162
Biotechnology Sector [Member] \| Corvium, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 53	$ 54
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	661,956	661,956
Biotechnology Sector [Member] \| Emalex Biosciences, Inc. [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate	12.07%	9.75%
Margin	790.00%	7.90%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 2,500
Investments at cost	1,962	2,420
Investments at fair value	1,962	2,420
Biotechnology Sector [Member] \| Emalex Biosciences, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	176	139
Investments at fair value	$ 263	$ 162
Number of Shares (in shares)	110,402	92,002
Biotechnology Sector [Member] \| Emalex Biosciences, Inc. [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.07%	9.75%
Margin	790.00%	7.90%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 2,500
Investments at cost	1,963	2,472
Investments at fair value	$ 1,963	$ 2,472
Biotechnology Sector [Member] \| Emalex Biosciences, Inc. [Member] \| Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.07%	9.75%
Margin	790.00%	7.90%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Nov. 01, 2025	Nov. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,923	4,896
Investments at fair value	$ 4,923	$ 4,896
Biotechnology Sector [Member] \| Emalex Biosciences, Inc. [Member] \| Term Loan, LIBOR Index, Four [Member]
Cash Rate	12.07%
Margin	790.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,912
Investments at fair value	4,912
Biotechnology Sector [Member] \| Emalex Biosciences, Inc. [Member] \| Common Stock [Member]
Investments at cost	356
Investments at fair value	$ 356
Number of Shares (in shares)	32,831
Biotechnology Sector [Member] \| Evelo Biosciences, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	11.75%
Margin	475.00%
Floor	11.00%
Ceiling Rate	0.00%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 15,000
Investments at cost	14,808
Investments at fair value	$ 14,808
Biotechnology Sector [Member] \| Evelo Biosciences, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	11.75%
Margin	475.00%
Floor	11.00%
Ceiling Rate	0.00%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 10,000
Investments at cost	9,872
Investments at fair value	9,872
Biotechnology Sector [Member] \| Evelo Biosciences, Inc. [Member] \| Common Stock Warrants [Member]
Investments at cost	126
Investments at fair value	$ 125
Number of Shares (in shares)	463,915
Biotechnology Sector [Member] \| Evelo Biosciences, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	11.75%
Margin	475.00%
Floor	11.00%
Ceiling Rate	0.00%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 6,000
Investments at cost	5,923
Investments at fair value	$ 5,923
Biotechnology Sector [Member] \| Evelo Biosciences, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	11.75%
Margin	475.00%
Floor	11.00%
Ceiling Rate	0.00%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 6,000
Investments at cost	5,923
Investments at fair value	$ 5,923
Biotechnology Sector [Member] \| Evelo Biosciences, Inc. [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	11.75%
Margin	475.00%
Floor	11.00%
Ceiling Rate	0.00%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 4,000
Investments at cost	3,949
Investments at fair value	$ 3,949
Biotechnology Sector [Member] \| Evelo Biosciences, Inc. [Member] \| Term Loan, Prime Index, Six [Member]
Cash Rate	11.75%
Margin	475.00%
Floor	11.00%
Ceiling Rate	0.00%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 4,000
Investments at cost	3,949
Investments at fair value	$ 3,949
Biotechnology Sector [Member] \| F-Star Therapeutics, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,473	2,463
Investments at fair value	$ 2,473	$ 2,463
Biotechnology Sector [Member] \| F-Star Therapeutics, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	625.00%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,465
Investments at fair value	2,476	2,465
Biotechnology Sector [Member] \| F-Star Therapeutics, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	35	36
Investments at fair value	$ 0	$ 3
Number of Shares (in shares)	21,120	21,120
Biotechnology Sector [Member] \| Imunon, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	$ 66	$ 65
Investments at fair value	$ 0	$ 1
Number of Shares (in shares)	16,502	295,053
Biotechnology Sector [Member] \| Greenlight Biosciences, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	575.00%	6.25%
Floor	9.00%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	4.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,430	2,475
Investments at fair value	$ 2,430	$ 2,475
Biotechnology Sector [Member] \| Greenlight Biosciences, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	575.00%	6.25%
Floor	9.00%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	4.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,857	4,850
Investments at fair value	4,857	$ 4,850
Biotechnology Sector [Member] \| Greenlight Biosciences, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	366
Investments at fair value	$ 0
Number of Shares (in shares)	47,452
Biotechnology Sector [Member] \| IMV Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.00%
Margin	575.00%	6.25%
Floor	9.00%	9.00%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,473	2,462
Investments at fair value	$ 2,473	$ 2,462
Biotechnology Sector [Member] \| IMV Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.00%
Margin	575.00%	6.25%
Floor	9.00%	9.00%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,946	4,799
Investments at fair value	4,946	4,799
Biotechnology Sector [Member] \| IMV Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	67	64
Investments at fair value	$ 0	$ 64
Number of Shares (in shares)	39,774	284,090
Biotechnology Sector [Member] \| IMV Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	575.00%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	$ 4,947
Biotechnology Sector [Member] \| IMV Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%
Margin	575.00%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	4,947
Biotechnology Sector [Member] \| LogicBio, Inc [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate		8.75%
Margin		6.25%
Floor		8.75%
Ceiling Rate		0.00%
ETP		4.50%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 4,028
Investments at cost		4,011
Investments at fair value		4,011
Biotechnology Sector [Member] \| LogicBio, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost		8
Investments at fair value		$ 0
Number of Shares (in shares)		7,843
Biotechnology Sector [Member] \| Mustang Bio, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	146	$ 146
Investments at fair value	$ 0	$ 5
Number of Shares (in shares)	252,161	252,161
Biotechnology Sector [Member] \| KSQ Therapeutics, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.25%
Margin	475.00%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,177
Investments at fair value	$ 6,177
Biotechnology Sector [Member] \| KSQ Therapeutics, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.25%
Margin	475.00%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,077
Investments at fair value	6,077
Biotechnology Sector [Member] \| KSQ Therapeutics, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	51
Investments at fair value	$ 60
Number of Shares (in shares)	48,077
Biotechnology Sector [Member] \| Provivi, Inc. [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate	12.67%	9.50%
Margin	850.00%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 5,000
Investments at cost	4,597	4,935
Investments at fair value	4,597	4,935
Biotechnology Sector [Member] \| Provivi, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	399	278
Investments at fair value	$ 648	$ 519
Number of Shares (in shares)	203,017	164,608
Biotechnology Sector [Member] \| Provivi, Inc. [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.67%	9.50%
Margin	850.00%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 5,000
Investments at cost	4,597	4,935
Investments at fair value	$ 4,597	$ 4,935
Biotechnology Sector [Member] \| Provivi, Inc. [Member] \| Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.67%	9.50%
Margin	850.00%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,280	2,440
Investments at fair value	$ 2,280	$ 2,440
Biotechnology Sector [Member] \| Provivi, Inc. [Member] \| Term Loan, LIBOR Index, Four [Member]
Cash Rate	12.67%	9.50%
Margin	850.00%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,280	2,440
Investments at fair value	$ 2,280	$ 2,440
Biotechnology Sector [Member] \| Provivi, Inc. [Member] \| Term Loan, LIBOR Index, Five [Member]
Cash Rate	12.67%	9.50%
Margin	850.00%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,274	2,430
Investments at fair value	$ 2,274	$ 2,430
Biotechnology Sector [Member] \| Provivi, Inc. [Member] \| Term Loan, LIBOR Index, Six [Member]
Cash Rate	12.67%	9.50%
Margin	850.00%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,274	2,430
Investments at fair value	2,274	2,430
Biotechnology Sector [Member] \| Getaround, Inc [Member] \| Common Stock [Member]
Investments at cost	253
Investments at fair value	$ 57
Number of Shares (in shares)	87,082
Biotechnology Sector [Member] \| Rocket Pharmaceuticals Corporation [Member] \| Common Stock Warrants [Member]
Investments at cost	$ 17	17
Investments at fair value	$ 14	$ 9
Number of Shares (in shares)	7,051	7,051
Biotechnology Sector [Member] \| Native Microbials, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.75%
Margin	525.00%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,469
Investments at fair value	$ 2,469
Biotechnology Sector [Member] \| Native Microbials, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.75%
Margin	525.00%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,630
Investments at fair value	3,630
Biotechnology Sector [Member] \| Native Microbials, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	64
Investments at fair value	$ 162
Number of Shares (in shares)	103,679
Biotechnology Sector [Member] \| PDS Biotechnology Corporation [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	575.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,697
Investments at fair value	$ 3,697
Biotechnology Sector [Member] \| PDS Biotechnology Corporation [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	575.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,701
Investments at fair value	9,701
Biotechnology Sector [Member] \| PDS Biotechnology Corporation [Member] \| Common Stock Warrants [Member]
Investments at cost	160
Investments at fair value	$ 3,024
Number of Shares (in shares)	299,848
Biotechnology Sector [Member] \| PDS Biotechnology Corporation [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	575.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,697
Investments at fair value	3,697
Biotechnology Sector [Member] \| Strongbridge U.S. Inc [Member] \| Common Stock Warrants [Member]
Investments at cost		$ 72
Investments at fair value		$ 110
Number of Shares (in shares)		160,714
Biotechnology Sector [Member] \| vTv Therapeutics Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	44	$ 44
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	95,293	95,293
Biotechnology Sector [Member] \| Xeris Pharmaceuticals, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	$ 72
Investments at fair value	$ 3
Number of Shares (in shares)	126,000
Biotechnology Sector [Member] \| HESP LLC [Member] \| Other Long-Term Investments [Member]
Investments at cost		$ 1,450
Investments at fair value		$ 0
Biotechnology Sector [Member] \| Controlled Affiliate [Member] \| Other Long-Term Investments [Member]
NAV %		0.00%
Medical Device Sector [Member]
Investments at cost	$ 132,803	$ 88,681
Investments at fair value	$ 135,960	$ 84,567
Medical Device Sector [Member] \| Swift Health Systems Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.25%
Margin	5.25%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,454
Investments at fair value	$ 3,454
Medical Device Sector [Member] \| Swift Health Systems Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.25%
Margin	5.25%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,349
Investments at fair value	3,349
Medical Device Sector [Member] \| Swift Health Systems Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	71
Investments at fair value	$ 83
Number of Shares (in shares)	135,484
Medical Device Sector [Member] \| Embody, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.00%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	28.00%	28.00%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,482	2,457
Investments at fair value	$ 2,482	$ 2,457
Medical Device Sector [Member] \| Magnolia Medical Technologies, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.00%	9.75%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,939	4,952
Investments at fair value	$ 4,939	$ 4,952
Medical Device Sector [Member] \| Magnolia Medical Technologies, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.00%	9.75%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,939	4,952
Investments at fair value	4,939	4,952
Medical Device Sector [Member] \| Magnolia Medical Technologies, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	194	91
Investments at fair value	$ 385	$ 112
Number of Shares (in shares)	809,931	441,780
Medical Device Sector [Member] \| Magnolia Medical Technologies, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	12.00%	9.75%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,933	4,944
Investments at fair value	$ 4,933	$ 4,944
Medical Device Sector [Member] \| Magnolia Medical Technologies, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	12.00%	9.75%
Margin	5.00%	5.00%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,933	4,944
Investments at fair value	$ 4,933	$ 4,944
Medical Device Sector [Member] \| Magnolia Medical Technologies, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	12.50%
Margin	5.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Medical Device Sector [Member] \| Magnolia Medical Technologies, Inc [Member] \| Term Loan, Prime Index, Six [Member]
Cash Rate	12.50%
Margin	5.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Medical Device Sector [Member] \| InfoBionic, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 1,000	$ 1,000
Investments at cost	974	963
Investments at fair value	$ 974	$ 963
Medical Device Sector [Member] \| InfoBionic, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 3,208	$ 3,500
Investments at cost	3,143	3,397
Investments at fair value	3,143	3,397
Medical Device Sector [Member] \| InfoBionic, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	124	124
Investments at fair value	$ 113	$ 121
Number of Shares (in shares)	317,647	317,647
Medical Device Sector [Member] \| Aerobiotix, LLC [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	$ 2,364
Medical Device Sector [Member] \| Aerobiotix, LLC [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	2,364
Medical Device Sector [Member] \| Aerobiotix, LLC [Member] \| Preferred Stock Warrants [Member]
Investments at cost	48
Investments at fair value	$ 31
Number of Shares (in shares)	27,330
Medical Device Sector [Member] \| Meditrina, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 83	$ 83
Investments at fair value	$ 101	$ 122
Number of Shares (in shares)	233,993	221,510
Medical Device Sector [Member] \| MacuLogix, Inc [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 7,500
Investments at cost		7,447
Investments at fair value		4,481
Medical Device Sector [Member] \| MacuLogix, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost		238
Investments at fair value		$ 0
Number of Shares (in shares)		454,460
Medical Device Sector [Member] \| MacuLogix, Inc [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 4,050
Investments at cost		4,022
Investments at fair value		$ 2,420
Medical Device Sector [Member] \| Canary Medical Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	7.00%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,489
Investments at fair value	$ 2,489
Medical Device Sector [Member] \| Canary Medical Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	9.00%
Margin	5.75%	5.75%
Floor	9.00%	9.00%
Ceiling Rate	0.00%	0.00%
ETP	7.00%	7.00%
Maturity Date	Nov. 01, 2024	Nov. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,475	2,394
Investments at fair value	2,475	2,394
Medical Device Sector [Member] \| Canary Medical Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	84	53
Investments at fair value	$ 1,864	$ 45
Number of Shares (in shares)	12,153	7,292
Medical Device Sector [Member] \| Canary Medical Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	7.00%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Medical Device Sector [Member] \| Scientia Vascular, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	11.75%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,706
Investments at fair value	$ 3,706
Medical Device Sector [Member] \| Scientia Vascular, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	11.75%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,597
Investments at fair value	3,597
Medical Device Sector [Member] \| Scientia Vascular, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	40
Investments at fair value	$ 46
Number of Shares (in shares)	19,662
Medical Device Sector [Member] \| Sonex Health, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.50%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	8.00%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,476
Investments at fair value	$ 2,476
Medical Device Sector [Member] \| Sonex Health, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	9.25%
Margin	6.50%	6.00%
Floor	9.75%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	8.00%	5.00%
Maturity Date	Jun. 01, 2025	Jun. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,391
Investments at fair value	2,476	2,391
Medical Device Sector [Member] \| Sonex Health, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	98	77
Investments at fair value	$ 123	$ 75
Number of Shares (in shares)	605,313	484,250
Medical Device Sector [Member] \| Sonex Health, Inc. [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Medical Device Sector [Member] \| Sonex Health, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	9.25%
Margin	6.50%	6.00%
Floor	9.75%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	8.00%	5.00%
Maturity Date	Jun. 01, 2025	Jun. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,472
Investments at fair value	$ 2,476	2,472
Medical Device Sector [Member] \| Sonex Health, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	8.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Medical Device Sector [Member] \| Sonex Health, Inc. [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	13.50%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	8.00%
Maturity Date	May 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,455
Investments at fair value	2,455
Medical Device Sector [Member] \| VERO Biotech LLC [Member] \| Preferred Stock Warrants [Member]
Investments at cost	53	53
Investments at fair value	$ 1	$ 30
Number of Shares (in shares)	408	408
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,973
Investments at fair value	$ 4,973
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,973
Investments at fair value	4,973
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,926
Investments at fair value		4,926
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	69	61
Investments at fair value	$ 209	$ 172
Number of Shares (in shares)	145,483	134,299
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,478
Investments at fair value	$ 2,478
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, LIBOR Index, Three [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,466
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,478
Investments at fair value	2,478
Medical Device Sector [Member] \| Ceribell, Inc. [Member] \| Term Loan, LIBOR Index, Four [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		2,466
Medical Device Sector [Member] \| Lumithera, Inc. [Member] \| Royalty Agreement [Member]
Investments at cost	1,200
Investments at fair value	1,100
Medical Device Sector [Member] \| Lumithera, Inc. [Member] \| Common Stock [Member]
Investments at cost	2,000
Investments at fair value	$ 1,700
Number of Shares (in shares)	392,651
Medical Device Sector [Member] \| ZetrOZ, Inc [Member] \| Royalty Agreement [Member]
Investments at cost	$ 0	0
Investments at fair value	$ 200	$ 200
Medical Device Sector [Member] \| Cognoa, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,932
Investments at fair value	$ 4,932
Medical Device Sector [Member] \| Cognoa, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,466
Investments at fair value	2,466
Medical Device Sector [Member] \| Cognoa, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	148
Investments at fair value	$ 179
Number of Shares (in shares)	775,000
Medical Device Sector [Member] \| Spineology, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.50%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	1.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,481
Investments at fair value	$ 2,481
Medical Device Sector [Member] \| Spineology, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	10.25%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling Rate	0.00%	0.00%
ETP	1.00%	1.00%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,966	4,928
Investments at fair value	$ 4,966	$ 4,928
Medical Device Sector [Member] \| Conventus Orthopaedics, Inc [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate	12.17%	9.25%
Margin	8.00%	8.00%
Floor	9.25%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 4,056
Investments at cost	3,898	4,009
Investments at fair value	3,898	4,009
Medical Device Sector [Member] \| Conventus Orthopaedics, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	221	149
Investments at fair value	$ 226	$ 169
Number of Shares (in shares)	7,972,222	6,361,111
Medical Device Sector [Member] \| Conventus Orthopaedics, Inc [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.17%	9.25%
Margin	8.00%	8.00%
Floor	9.25%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 4,056
Investments at cost	3,898	4,009
Investments at fair value	$ 3,898	$ 4,009
Medical Device Sector [Member] \| Corinth Medtech, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.25%	8.50%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling Rate	0.00%	0.00%
ETP	20.00%	20.00%
Maturity Date	Sep. 15, 2022	Apr. 01, 2022
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,500	2,495
Investments at fair value	$ 2,500	$ 2,495
Medical Device Sector [Member] \| Corinth Medtech, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.25%	8.50%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling Rate	0.00%	0.00%
ETP	20.00%	20.00%
Maturity Date	Sep. 15, 2022	Apr. 01, 2022
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,500	2,495
Investments at fair value	2,500	2,495
Medical Device Sector [Member] \| AccuVein Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	24	24
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	1,175	1,175
Medical Device Sector [Member] \| Tigo Energy, Inc. [Member] \| Preferred Stock [Member]
Investments at cost	$ 8
Investments at fair value	$ 27
Number of Shares (in shares)	22,313
Medical Device Sector [Member] \| Aerin Medical, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 64	$ 66
Investments at fair value	$ 1,200	$ 463
Number of Shares (in shares)	1,818,183	1,818,183
Medical Device Sector [Member] \| CSA Medical, Inc [Member] \| Term Loan, LIBOR Index, One [Member]
Cash Rate	12.37%	10.00%
Margin	8.20%	8.20%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 1,625	$ 3,125
Investments at cost	1,610	3,095
Investments at fair value	1,610	3,095
Medical Device Sector [Member] \| CSA Medical, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	153	154
Investments at fair value	$ 150	$ 108
Number of Shares (in shares)	1,375,727	1,375,727
Medical Device Sector [Member] \| CSA Medical, Inc [Member] \| Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.37%	10.00%
Margin	8.20%	8.20%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 108	$ 208
Investments at cost	107	206
Investments at fair value	$ 107	$ 206
Medical Device Sector [Member] \| CSA Medical, Inc [Member] \| Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.37%	10.00%
Margin	8.20%	8.20%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	5.00%
Maturity Date	Mar. 01, 2024	Mar. 01, 2024
Principal Amount	$ 2,000	$ 3,600
Investments at cost	1,983	3,569
Investments at fair value	1,983	3,569
Medical Device Sector [Member] \| CVRx, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	76	80
Investments at fair value	$ 394	$ 90
Number of Shares (in shares)	47,410	47,410
Medical Device Sector [Member] \| Robin Healthcare, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,500
Investments at cost	3,460
Investments at fair value	$ 3,460
Medical Device Sector [Member] \| Robin Healthcare, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,500
Investments at cost	3,360
Investments at fair value	3,360
Software Sector [Member]
Investments at cost	120,157	$ 60,902
Investments at fair value	$ 118,716	$ 60,807
Software Sector [Member] \| DropOff, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.00%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,859	5,816
Investments at fair value	$ 5,859	$ 5,816
Software Sector [Member] \| DropOff, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.00%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,500	$ 6,500
Investments at cost	6,347	6,087
Investments at fair value	6,347	6,087
Software Sector [Member] \| DropOff, Inc. [Member] \| Common Stock Warrants [Member]
Investments at cost	455	397
Investments at fair value	$ 197	$ 395
Number of Shares (in shares)	516,732	482,283
Software Sector [Member] \| DropOff, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	14.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,436
Investments at fair value	$ 2,436
Software Sector [Member] \| Engage3, LLC [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,718
Investments at fair value	$ 3,718
Software Sector [Member] \| Engage3, LLC [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,678
Investments at fair value	3,678
Software Sector [Member] \| BrightInsight, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	160
Investments at fair value	$ 170
Number of Shares (in shares)	80,544
Software Sector [Member] \| Groundspeed Analytics, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	11.00%
Ceiling Rate	18.00%
ETP	3.00%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,948
Investments at fair value	$ 4,948
Software Sector [Member] \| Groundspeed Analytics, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	11.00%
Ceiling Rate	18.00%
ETP	3.00%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,798
Investments at fair value	4,798
Software Sector [Member] \| Groundspeed Analytics, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	6
Investments at fair value	$ 6
Number of Shares (in shares)	86,300
Software Sector [Member] \| Medsphere Systems Corporation [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 60	$ 60
Investments at fair value	$ 359	$ 195
Number of Shares (in shares)	7,097,792	7,097,792
Software Sector [Member] \| Kodiak Robotics, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,826
Investments at fair value	$ 9,826
Software Sector [Member] \| Kodiak Robotics, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,826
Investments at fair value	9,826
Software Sector [Member] \| Kodiak Robotics, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	273
Investments at fair value	$ 296
Number of Shares (in shares)	639,918
Software Sector [Member] \| Kodiak Robotics, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Software Sector [Member] \| Kodiak Robotics, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Software Sector [Member] \| Lemongrass Holdings, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 2,474
Software Sector [Member] \| Lemongrass Holdings, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	4,947
Software Sector [Member] \| Lemongrass Holdings, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	34
Investments at fair value	$ 41
Number of Shares (in shares)	101,308
Software Sector [Member] \| Lytics, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.00%
Margin	6.00%
Floor	12.25%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 1,250
Investments at cost	1,231
Investments at fair value	$ 1,231
Software Sector [Member] \| Lytics, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.00%	9.25%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	4.00%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,396	2,464
Investments at fair value	2,396	2,464
Software Sector [Member] \| Lytics, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	40	12
Investments at fair value	$ 44	$ 12
Number of Shares (in shares)	80,197	26,733
Software Sector [Member] \| Reputation Institute, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0.00%	0.00%
ETP	3.00%	3.00%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,932	4,905
Investments at fair value	4,932	4,905
Software Sector [Member] \| Reputation Institute, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	56	54
Investments at fair value	$ 39	$ 52
Number of Shares (in shares)	3,731	3,731
Software Sector [Member] \| Slingshot Aerospace, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,933
Investments at fair value	$ 4,933
Software Sector [Member] \| Slingshot Aerospace, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,870
Investments at fair value	4,870
Software Sector [Member] \| Slingshot Aerospace, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	123
Investments at fair value	$ 133
Number of Shares (in shares)	309,208
Software Sector [Member] \| Slingshot Aerospace, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,933
Investments at fair value	$ 4,933
Software Sector [Member] \| Slingshot Aerospace, Inc. [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,933
Investments at fair value	4,933
Software Sector [Member] \| Branded Online, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Nov. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,355
Investments at fair value		$ 2,355
Software Sector [Member] \| Branded Online, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Sep. 01, 2026
Principal Amount		$ 5,000
Investments at cost		4,719
Investments at fair value		4,719
Software Sector [Member] \| Branded Online, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost		370
Investments at fair value		$ 443
Number of Shares (in shares)		16,678
Software Sector [Member] \| Branded Online, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		0.00%
Maturity Date		Jul. 01, 2023
Principal Amount		$ 5,000
Investments at cost		5,000
Investments at fair value		$ 5,000
Software Sector [Member] \| Branded Online, Inc [Member] \| Common Stock [Member]
Investments at cost	1,079
Investments at fair value	$ 83
Number of Shares (in shares)	108,004
Software Sector [Member] \| Decisyon, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	16.93%	12.68%
Margin	9.43%	9.23%
Floor	12.68%	12.68%
Ceiling Rate	0.00%	0.00%
ETP	50.43%	50.43%
Maturity Date	Dec. 31, 2022	Jan. 01, 2023
Principal Amount	$ 3,295	$ 3,470
Investments at cost	3,295	3,470
Investments at fair value	3,295	3,470
Software Sector [Member] \| Decisyon, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	46	46
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	82,967	82,967
Software Sector [Member] \| Decisyon, Inc [Member] \| Preferred and Common Stock [Member]
Investments at cost	$ 230	$ 230
Investments at fair value	$ 0	$ 120
Number of Shares (in shares)	72,638,663	72,638,663
Software Sector [Member] \| Supply Network Visiblity Holdings LLC [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,472	3,458
Investments at fair value	$ 3,472	$ 3,458
Software Sector [Member] \| Supply Network Visiblity Holdings LLC [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,472	3,458
Investments at fair value	3,472	3,458
Software Sector [Member] \| Supply Network Visiblity Holdings LLC [Member] \| Preferred Stock Warrants [Member]
Investments at cost	64	64
Investments at fair value	$ 83	$ 62
Number of Shares (in shares)	682	682
Software Sector [Member] \| Supply Network Visiblity Holdings LLC [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,472	2,463
Investments at fair value	$ 2,472	$ 2,463
Software Sector [Member] \| Supply Network Visiblity Holdings LLC [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,472	2,463
Investments at fair value	$ 2,472	$ 2,463
Software Sector [Member] \| Britecore Holdings, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	10.50%
Margin	6.75%	7.25%
Floor	10.00%	10.50%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	4.00%
Maturity Date	Mar. 01, 2026	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,487	2,481
Investments at fair value	$ 2,487	$ 2,481
Software Sector [Member] \| Britecore Holdings, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	10.50%
Margin	6.75%	7.25%
Floor	10.00%	10.50%
Ceiling Rate	0.00%	0.00%
ETP	5.00%	4.00%
Maturity Date	Mar. 01, 2026	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,421	2,481
Investments at fair value	2,421	2,481
Software Sector [Member] \| Britecore Holdings, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	21	5
Investments at fair value	$ 69	$ 37
Number of Shares (in shares)	77,828	55,591
Software Sector [Member] \| E La Carte, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,958
Investments at fair value		$ 2,958
Software Sector [Member] \| E La Carte, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,937
Investments at fair value		2,937
Software Sector [Member] \| E La Carte, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	$ 60
Investments at fair value	$ 3
Number of Shares (in shares)	147,361
Software Sector [Member] \| E La Carte, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost		61
Investments at fair value		$ 53
Number of Shares (in shares)		181,947
Software Sector [Member] \| E La Carte, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 1,500
Investments at cost		1,479
Investments at fair value		1,479
Software Sector [Member] \| Lotame Solutions, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 22	23
Investments at fair value	$ 312	$ 276
Number of Shares (in shares)	288,115	288,115
Software Sector [Member] \| Revinate Holdings, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 46	$ 44
Investments at fair value	$ 99	$ 66
Number of Shares (in shares)	682,034	615,475
Software Sector [Member] \| Riv Data Corp [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 12	$ 12
Investments at fair value	$ 296	$ 292
Number of Shares (in shares)	321,428	321,428
Software Sector [Member] \| SIGNiX, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 225	$ 224
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	186,235	186,235
Software Sector [Member] \| Skyword, Inc [Member] \| Warrant [Member]
Investments at cost	$ 48	$ 49
Investments at fair value	$ 1	$ 4
Number of Shares (in shares)	301,055	301,055
Software Sector [Member] \| Topia Mobility, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 138	$ 138
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	3,049,607	3,049,607
Software Sector [Member] \| xAd, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 177	$ 179
Investments at fair value	$ 12	$ 1
Number of Shares (in shares)	4,343,348	4,343,348
Diagnostics Sector [Member]
Investments at cost	$ 9,851	$ 12,393
Investments at fair value	$ 9,858	$ 12,377
Diagnostics Sector [Member] \| Hound Labs, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.50%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Diagnostics Sector [Member] \| Hound Labs, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.50%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,385
Investments at fair value	2,385
Diagnostics Sector [Member] \| Hound Labs, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost	47
Investments at fair value	$ 54
Number of Shares (in shares)	159,893
Diagnostics Sector [Member] \| Hound Labs, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.50%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,946
Investments at fair value	4,946
Diagnostics Sector [Member] \| IDbyDNA, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,936
Investments at fair value		$ 4,936
Diagnostics Sector [Member] \| IDbyDNA, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,902
Investments at fair value		4,902
Diagnostics Sector [Member] \| IDbyDNA, Inc. [Member] \| Preferred Stock Warrants [Member]
Investments at cost		112
Investments at fair value		$ 95
Number of Shares (in shares)		472,006
Diagnostics Sector [Member] \| IDbyDNA, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,444
Investments at fair value		2,444
Communications Sector [Member]
Investments at cost	22,892	22,853
Investments at fair value	$ 26,176	$ 25,920
Communications Sector [Member] \| Axiom Space, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.00%	9.25%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,455	7,442
Investments at fair value	$ 7,455	$ 7,442
Communications Sector [Member] \| Axiom Space, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.00%	9.25%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,455	7,442
Investments at fair value	7,455	7,442
Communications Sector [Member] \| Axiom Space, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	46	45
Investments at fair value	$ 67	$ 42
Number of Shares (in shares)	1,991	1,991
Communications Sector [Member] \| Axiom Space, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.00%	9.25%
Margin	6.00%	6.00%
Floor	9.25%	9.25%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,455	7,442
Investments at fair value	$ 7,455	$ 7,442
Communications Sector [Member] \| Axiom Space, Inc [Member] \| Convertible Note (3.00%, Due 7/1/23) [Member]
Cash Rate	3.00%	3.00%
Maturity Date	Jul. 01, 2023	Jul. 01, 2023
Principal Amount	$ 250	$ 250
Investments at cost	250	250
Investments at fair value	306	250
Communications Sector [Member] \| Intelepeer Holdings, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	139	140
Investments at fair value	$ 3,265	$ 3,141
Number of Shares (in shares)	2,936,535	2,936,535
Communications Sector [Member] \| PebblePost, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 173	$ 161
Number of Shares (in shares)	598,850	598,850
Life Science [Member] \| Non-affiliate [Member] \| Warrant [Member]
NAV %		1.00%
Life Science [Member] \| Non-affiliate [Member] \| Debt Investments [Member]
Investments at cost	$ 318,172
Investments at fair value	$ 317,568
NAV %	99.70%
Other Healthcare Sector [Member] \| Kate Farms, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 102	$ 101
Investments at fair value	$ 1,370	$ 1,177
Number of Shares (in shares)	82,965	82,965
Other Healthcare Sector [Member] \| Secure Transfusion Services, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Dec. 31, 2025
Principal Amount	$ 2,500
Investments at cost	2,467
Investments at fair value	$ 832
Other Healthcare Sector [Member] \| Secure Transfusion Services, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 4,943
Investments at cost	4,943
Investments at fair value	1,668
Other Healthcare Sector [Member] \| Secure Transfusion Services, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	47
Investments at fair value	$ 0
Number of Shares (in shares)	77,690
Other Healthcare Sector [Member] \| Watermark Medical, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost		$ 74
Investments at fair value		$ 0
Number of Shares (in shares)		27,373
Other Sustainability Sector [Member]
Investments at cost	$ 84,633	$ 46,595
Investments at fair value	$ 85,524	$ 47,011
Other Sustainability Sector [Member] \| Aerofarms, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,699
Investments at fair value	$ 3,699
Other Sustainability Sector [Member] \| Aerofarms, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,699
Investments at fair value	3,699
Other Sustainability Sector [Member] \| Dream Holdings, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	16
Investments at fair value	$ 16
Number of Shares (in shares)	86,066
Other Sustainability Sector [Member] \| Nexii Building Solutions, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	10.25%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,371	7,322
Investments at fair value	$ 7,371	$ 7,322
Other Sustainability Sector [Member] \| Nexii Building Solutions, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	10.25%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,371	7,322
Investments at fair value	7,371	7,322
Other Sustainability Sector [Member] \| Nexii Building Solutions, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	488	356
Investments at fair value	$ 1,061	$ 331
Number of Shares (in shares)	204,832	142,405
Other Sustainability Sector [Member] \| Nexii Building Solutions, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	14.50%	10.25%
Margin	7.00%	7.00%
Floor	10.25%	10.25%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,371	7,322
Investments at fair value	$ 7,371	$ 7,322
Other Sustainability Sector [Member] \| Nexii Building Solutions, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	14.50%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,903
Investments at fair value	$ 4,903
Other Sustainability Sector [Member] \| Nexii Building Solutions, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	14.50%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,903
Investments at fair value	$ 4,903
Other Sustainability Sector [Member] \| Soli Organic, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	$ 4,927
Other Sustainability Sector [Member] \| Soli Organic, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	2,463
Other Sustainability Sector [Member] \| Soli Organic, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	214
Investments at fair value	$ 361
Number of Shares (in shares)	681
Other Sustainability Sector [Member] \| Soli Organic, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,924
Investments at fair value	$ 4,924
Other Sustainability Sector [Member] \| Soli Organic, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,462
Other Sustainability Sector [Member] \| Soli Organic, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,900
Investments at fair value	$ 4,900
Other Sustainability Sector [Member] \| Soli Organic, Inc [Member] \| Term Loan, Prime Index, Six [Member]
Cash Rate	13.00%
Margin	5.50%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,450
Investments at fair value	2,450
Other Sustainability Sector [Member] \| LiquiGlide, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 2,000
Investments at cost		1,928
Investments at fair value		1,928
Other Sustainability Sector [Member] \| LiquiGlide, Inc [Member] \| Common Stock Warrants [Member]
Investments at cost	39	39
Investments at fair value	$ 55	$ 36
Number of Shares (in shares)	61,539	61,359
Other Sustainability Sector [Member] \| Temperpack Technologies, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,717	3,703
Investments at fair value	$ 3,717	$ 3,703
Other Sustainability Sector [Member] \| Temperpack Technologies, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,697	3,703
Investments at fair value	3,697	3,703
Other Sustainability Sector [Member] \| Temperpack Technologies, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	126	107
Investments at fair value	$ 268	$ 552
Number of Shares (in shares)	35,906	48,756
Other Sustainability Sector [Member] \| Temperpack Technologies, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,424	7,396
Investments at fair value	$ 7,424	$ 7,396
Other Sustainability Sector [Member] \| Temperpack Technologies, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,712	3,698
Investments at fair value	$ 3,712	$ 3,698
Other Sustainability Sector [Member] \| Temperpack Technologies, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	14.25%	10.00%
Margin	6.75%	6.75%
Floor	10.00%	10.00%
Ceiling Rate	0.00%	0.00%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,712	3,698
Investments at fair value	3,712	3,698
Healthcare Information and Services Segment [Member] \| Non-affiliate [Member] \| Warrant [Member]
Investments at cost	416	347
Investments at fair value	$ 1,953	$ 1,467
NAV %	0.60%	0.60%
Healthcare Information and Services Segment [Member] \| Non-affiliate [Member] \| Debt Investments [Member]
Investments at cost	$ 30,729	$ 12,282
Investments at fair value	$ 25,819	$ 12,282
NAV %	8.10%	5.00%
Life Science Segment [Member] \| Non-affiliate [Member] \| Warrant [Member]
Investments at cost	$ 4,197	$ 2,893
Investments at fair value	$ 9,792	2,600
NAV %	3.10%
Life Science Segment [Member] \| Non-affiliate [Member] \| Debt Investments [Member]
Investments at cost		194,237
Investments at fair value		$ 189,669
NAV %		77.30%
Networking Sector [Member]
Investments at cost	$ 11,831	$ 17,390
Investments at fair value	$ 11,710	$ 17,964
Networking Sector [Member] \| Liqid, Inc [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 3,333	$ 5,000
Investments at cost	3,286	4,924
Investments at fair value	$ 3,286	$ 4,924
Networking Sector [Member] \| Liqid, Inc [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 3,333	$ 5,000
Investments at cost	3,286	4,770
Investments at fair value	3,286	4,770
Networking Sector [Member] \| Liqid, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	364	364
Investments at fair value	$ 243	$ 938
Number of Shares (in shares)	344,102	344,102
Networking Sector [Member] \| Liqid, Inc [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,667	$ 2,500
Investments at cost	1,641	2,459
Investments at fair value	$ 1,641	$ 2,459
Networking Sector [Member] \| Liqid, Inc [Member] \| Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,667	$ 2,500
Investments at cost	1,641	2,459
Investments at fair value	$ 1,641	$ 2,459
Networking Sector [Member] \| Liqid, Inc [Member] \| Term Loan, Prime Index, Five [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0.00%	0.00%
ETP	4.00%	4.00%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,667	$ 2,500
Investments at cost	1,613	2,414
Investments at fair value	1,613	2,414
Sustainability Segment [Member] \| Non-affiliate [Member] \| Warrant [Member]
Investments at cost	928	502
Investments at fair value	$ 1,819	$ 919
NAV %	0.60%	0.40%
Sustainability Segment [Member] \| Non-affiliate [Member] \| Debt Investments [Member]
Investments at cost	$ 83,705	$ 46,092
Investments at fair value	$ 83,705	$ 46,092
NAV %	26.30%	18.80%
Data Storage [Member] \| CPG Beyond, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost		$ 242
Investments at fair value		$ 859
Number of Shares (in shares)		500,000
Data Storage [Member] \| Silk, Inc [Member] \| Warrant [Member]
Investments at cost		$ 234
Investments at fair value		$ 188
Number of Shares (in shares)		44,211,003
Internet and Media Sector [Member]
Investments at cost	$ 329	$ 569
Investments at fair value	1,159	3,305
Internet and Media Sector [Member] \| Global Worldwide LLC [Member] \| Preferred Stock Warrants [Member]
Investments at cost	75	75
Investments at fair value	$ 0	$ 6
Number of Shares (in shares)	245,810	245,810
Internet and Media Sector [Member] \| Rocket Lawyer Incorporated [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 357	$ 741
Number of Shares (in shares)	261,721	261,721
Internet and Media Sector [Member] \| Skillshare, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 162	$ 162
Investments at fair value	$ 802	$ 2,403
Number of Shares (in shares)	139,074	139,074
Internet and Media Sector [Member] \| Zeta Global Holdings Corp [Member] \| Common Stock [Member]
Investments at cost		$ 240
Investments at fair value		$ 155
Number of Shares (in shares)		18,405
Power Management Sector [Member]
Investments at cost	$ 1,585	$ 1,585
Investments at fair value	2,610	2,609
Power Management Sector [Member] \| Kinestral, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost		1,585
Investments at fair value		$ 2,609
Number of Shares (in shares)		5,002,574
Power Management Sector [Member] \| Halio, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	1,585
Investments at fair value	$ 2,610
Number of Shares (in shares)	5,002,574
Technology Segment [Member] \| Non-affiliate [Member] \| Warrant [Member]
Investments at cost	$ 9,249	$ 6,281
Investments at fair value	$ 16,148	$ 15,214
NAV %	5.10%	6.20%
Technology Segment [Member] \| Non-affiliate [Member] \| Debt Investments [Member]
Investments at cost	$ 268,468	$ 189,274
Investments at fair value	$ 259,366	$ 189,274
NAV %	81.40%	77.20%
Semiconductor Sector [Member]
Investments at cost	$ 56	$ 101
Investments at fair value	0	0
Semiconductor Sector [Member] \| Avalanche Technology, Inc [Member] \| Warrant [Member]
Investments at cost	56	101
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	6,081	6,753
Software, Healthcare Information and Service [Member]
Investments at cost	$ 13,735	$ 60
Investments at fair value	$ 14,044	195
Software, Healthcare Information and Service [Member] \| BrightInsight, Inc. [Member] \| Term Loan, Prime Index Two [Member]
Cash Rate	12.50%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,448
Investments at fair value	$ 3,448
Software, Healthcare Information and Service [Member] \| BrightInsight, Inc. [Member] \| Term Loan, Prime Index, One [Member]
Cash Rate	12.50%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 7,000
Investments at cost	6,619
Investments at fair value	$ 6,619
Software, Healthcare Information and Service [Member] \| BrightInsight, Inc. [Member] \| Term Loan, Prime Index Three [Member]
Cash Rate	12.50%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,448
Investments at fair value	3,448
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,316	$ 1,047
Data Storage Sector [Member] \| CPG Beyond, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	242
Investments at fair value	$ 909
Number of Shares (in shares)	500,000
Data Storage Sector [Member] \| Silk, Inc [Member] \| Preferred Stock Warrants [Member]
Investments at cost	$ 234
Investments at fair value	$ 407
Number of Shares (in shares)	442,110

Consolidated Schedule of Investments - Investments (Details) (Parentheticals)	Dec. 31, 2022	Dec. 31, 2021
NAV %	226.10%	186.70%
Non-affiliate [Member]
NAV %	226.10%	186.70%
Controlled Affiliate [Member]
NAV %		0.00%
Warrant [Member] \| Non-affiliate [Member]
NAV %	9.40%	8.20%
Warrant [Member] \| Non-affiliate [Member] \| Healthcare Information and Services Segment [Member]
NAV %	0.60%	0.60%
Warrant [Member] \| Non-affiliate [Member] \| Life Science Segment [Member]
NAV %	3.10%
Warrant [Member] \| Non-affiliate [Member] \| Life Science [Member]
NAV %		1.00%
Warrant [Member] \| Non-affiliate [Member] \| Sustainability Segment [Member]
NAV %	0.60%	0.40%
Warrant [Member] \| Non-affiliate [Member] \| Technology Segment [Member]
NAV %	5.10%	6.20%
Other Long-Term Investments [Member] \| Non-affiliate [Member]
NAV %	0.40%	0.10%
Other Long-Term Investments [Member] \| Controlled Affiliate [Member] \| Biotechnology Sector [Member]
NAV %		0.00%
Equity Securities [Member] \| Non-affiliate [Member]
NAV %	0.80%	0.10%
Unrestricted Short Term Investments [Member]
NAV %	2.20%	3.20%
Restricted Short Term Investments [Member]
NAV %	0.90%	0.60%
Debt Investments [Member] \| Non-affiliate [Member]
NAV %	215.50%	178.30%
Debt Investments [Member] \| Non-affiliate [Member] \| Healthcare Information and Services Segment [Member]
NAV %	8.10%	5.00%
Debt Investments [Member] \| Non-affiliate [Member] \| Life Science Segment [Member]
NAV %		77.30%
Debt Investments [Member] \| Non-affiliate [Member] \| Life Science [Member]
NAV %	99.70%
Debt Investments [Member] \| Non-affiliate [Member] \| Sustainability Segment [Member]
NAV %	26.30%	18.80%
Debt Investments [Member] \| Non-affiliate [Member] \| Technology Segment [Member]
NAV %	81.40%	77.20%

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		2 Months Ended	4 Months Ended	12 Months Ended			20 Months Ended
	Mar. 14, 2022	Mar. 03, 2022	Apr. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Apr. 23, 2022	Aug. 02, 2021	Jul. 30, 2020	Aug. 02, 2019
Investments, Nonaccrual, Interest Income				$ 0	$ 1,300	$ 30
Investment, Nonaccrual, Income Not Received in Cash, Percent				7.40%	5.90%	5.80%
Debt Issuance Costs, Net, Total		$ 7,100			$ 4,300
Deferred Finance Costs, Accumulated Amortization		4,800			3,200
Amortization of Debt Issuance Costs		1,600		$ 1,604	1,091	$ 1,018
Adjustments to Additional Paid in Capital, Non-deductible Excise Taxes Paid		$ 700			400	200
Federal Excise Tax, Percent		4.00%		4.00%			4.00%
Excise and Sales Taxes		$ 700		$ 715	401	222
Unrecognized Tax Benefits, Ending Balance				$ 0	0		$ 0
Open Tax Year				2019 2020 2021
Proceeds from Issuance of Common Stock				$ 84,603	$ 30,086	$ 44,611
Stock Repurchase Program, Remaining Authorized Repurchase Amount								$ 5,000
Stock Repurchased During Period, Shares (in shares)				0	0	0	167,465
Stock Repurchased During Period, Per Share (in dollars per share)							$ 11.22
Stock Repurchased During Period, Value							$ 1,900
The 2019 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value											$ 50,000
The 2020 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value										$ 100,000
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value									$ 100,000
Stock Issued During Period, Shares, New Issues (in shares)				3,982,684
Proceeds from Issuance of Common Stock				$ 50,300
Payments of Stock Issuance Costs				1,000
Equity Sales Agreement, Remaining Amount Available for Issuance				$ 31,500			$ 31,500
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,500,000
Shares Issued, Price Per Share (in dollars per share)	$ 14.35
Proceeds from Issuance of Common Stock	$ 34,300
The 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					1,907,234
Proceeds from Issuance of Common Stock					$ 30,100
Payments of Stock Issuance Costs					800
The 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						3,702,500
Proceeds from Issuance of Common Stock						$ 44,600
Payments of Stock Issuance Costs						$ 1,000
HSLFI [Member]
Dividend Income, Operating, Total			$ 0
Three Investments [Member]
Investments, Cost, Nonaccrual Status		20,900
Investments, Fair Value, Nonaccrual Status		$ 8,300
One Investment [Member]
Investments, Cost, Nonaccrual Status					11,500
Investments, Fair Value, Nonaccrual Status					$ 6,900

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands			12 Months Ended
	Oct. 22, 2021	Oct. 30, 2018	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Management Fee Payable			$ 1,065	$ 706
Management Fee Expense			10,566	7,617	$ 6,458
Performance Based Incentive Fee			7,745	7,055	5,187
Incentive Fee Payable			1,392	2,015
Administrative Fees Expense			$ 1,667	1,285	1,016
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent		2.00%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million			1.60%
Management Fee Payable			$ 1,100	700
Management Fee Expense			10,600	7,600	6,500
Incentive Fee to Pre-incentive Net Investment Income	20.00%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7.00%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100.00%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Performance Based Incentive Fee			7,700	7,100	5,200
Incentive Fee Cap and Deferral Mechanism Reduction to Expense			1,000
Incentive Fee Payable			1,400	2,000
Administration Agreement [Member]
Administrative Fees Expense			$ 1,700	$ 1,300	$ 1,000

Note 4 - Investments (Details Textual) - USD ($) $ in Thousands		4 Months Ended	24 Months Ended	21840 Months Ended
	Apr. 21, 2020	Apr. 21, 2020	Jun. 04, 2020	Feb. 25, 2022	Jun. 19, 2019	Jun. 01, 2018
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000	$ 100,000		$ 200,000		$ 100,000
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature	$ 200,000	$ 200,000				$ 200,000
Line of Credit Facility, Advance Rate	67.00%	67.00%			67.00%
NYL Facility [Member] \| USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				3.00%
NYL Facility [Member] \| USD Mid-market Wwap Rate [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	3.55%		2.75%
NYL Facility [Member] \| USD Mid-market Wwap Rate [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	5.15%		3.25%
HSLFI [Member]
Payments to Acquire Investments, Total	$ 17,100
Consideration Transferred, Percentage of Warrants Held by Investment	50.00%
Dividend Income, Operating, Total		$ 0

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Investments at cost	$ 721,248	$ 453,837
Investments at fair value	720,026	458,075
Biotechnology Sector [Member]
Investments at cost	193,372	109,899
Investments at fair value	195,006	107,902
Medical Device Sector [Member]
Investments at cost	132,803	88,681
Investments at fair value	135,960	84,567
Communications Sector [Member]
Investments at cost	22,892	22,853
Investments at fair value	26,176	25,920
Consumer-related Sector [Member]
Investments at cost	121,961	92,158
Investments at fair value	114,050	93,194
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,316	1,047
Internet and Media Sector [Member]
Investments at cost	329	569
Investments at fair value	1,159	3,305
Networking Sector [Member]
Investments at cost	11,831	17,390
Investments at fair value	11,710	17,964
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,610	2,609
Semiconductor Sector [Member]
Investments at cost	56	101
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	120,157	60,902
Investments at fair value	118,716	60,807
Energy Efficiency [Member]
Investments at cost	8	0
Investments at fair value	27	0
Other Sustainability Sector [Member]
Investments at cost	84,633	46,595
Investments at fair value	85,524	47,011
Diagnostics Sector [Member]
Investments at cost	9,851	12,393
Investments at fair value	9,858	12,377
Other Sector [Member]
Investments at cost	7,559	175
Investments at fair value	3,870	1,177
Software, Healthcare Information and Service [Member]
Investments at cost	13,735	60
Investments at fair value	14,044	195
Debt [Member]
Investments at cost	701,074	441,885
Investments at fair value	686,458	437,317
Warrant [Member]
Investments at cost	14,790	10,023
Investments at fair value	29,712	20,200
Other Debt Obligations [Member]
Investments at cost	1,200	1,450
Investments at fair value	1,300	200
Equity Securities [Member]
Investments at cost	4,184	479
Investments at fair value	$ 2,556	$ 358

Note 4 - Investments - Selected Statements of Operations (Details) - USD ($) $ in Thousands	4 Months Ended	12 Months Ended			16 Months Ended
	Apr. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 21, 2021
Interest income on investments		$ 77,366	$ 54,411	$ 42,192
Total investment income		79,191	60,015	46,035
Total expenses		42,289	31,394	25,064
Net investment income		36,187	28,220	20,749
Net realized gain on investments		(9,484)	(3,248)	(14,698)
Net unrealized appreciation on investments		(5,552)	3,205	313
Net increase in net assets resulting from operations		$ 21,151	$ 27,782	$ 6,364
HSLFI [Member]
Interest income on investments	$ 1,353				$ 1,353
Total investment income	1,465				1,465
Total expenses	1,229				1,229
Net investment income	236				236
Net realized gain on investments	120				120
Net unrealized appreciation on investments	(392)				(392)
Net increase in net assets resulting from operations	$ (36)				$ (36)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Net unrealized (depreciation) appreciation on investments

Note 5 - Transactions With Affiliated Companies - Investments in Controlled Affiliated Companies (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

$ (5,552)

$ 3,205

$ 313

(9,484)

(3,248)

(14,698)

1,500

(300)

(50)

Net unrealized (depreciation) appreciation on investments

1,450

(1,450)

(1,150)

1,500

Controlled Affiliate [Member]

Dividends declared

1,500

(300)

(50)

Net unrealized (depreciation) appreciation on investments

1,450

(1,450)

(1,150)

1,500

Other Affiliates [Member]

Dividends declared

7,547

800

(3,583)

(3,538)

Net unrealized (depreciation) appreciation on investments

(848)

(390)

7,547

Other Affiliates [Member] | First Decisyon Inc. Investment [Member]

252

^[1]

1,181

^[1]

^[1]

^[1]

(1,181)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

1,181

Other Affiliates [Member] | Second Decisyon Inc. Investment [Member]

^[1]

^[1]

626

^[1]

^[1]

^[1]

(638)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

626

Other Affiliates [Member] | Third Decisyon Inc. Investment [Member]

^[1]

^[1]

227

^[1]

^[1]

^[1]

(227)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

227

Other Affiliates [Member] | Fourth Decisyon Inc. Investment [Member]

^[1]

^[1]

228

^[1]

^[1]

^[1]

(228)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

228

Other Affiliates [Member] | Fifth Decisyon Inc. Investment [Member]

^[1]

^[1]

685

^[1]

^[1]

^[1]

(685)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

685

Other Affiliates [Member] | Sixth Decisyon Inc. Investment [Member]

^[1]

^[1]

276

^[1]

^[1]

^[1]

(276)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

276

Other Affiliates [Member] | Seventh Decisyon Inc. Investment [Member]

^[1]

^[1]

183

^[1]

^[1]

^[1]

(183)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

183

Other Affiliates [Member] | Eighth Decisyon Inc. Investment [Member]

^[1]

^[1]

120

^[1]

^[1]

(120)

Net unrealized (depreciation) appreciation on investments

^[1]

^[1]

^[1]

^[1]

120

Other Affiliates [Member] | First MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]

^[1]

2,382

(2,783)

Net unrealized (depreciation) appreciation on investments

401

2,382

Other Affiliates [Member] | Second MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]

139

250

(250)

Net unrealized (depreciation) appreciation on investments

Other Affiliates [Member] | Third MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]

(70)

Net unrealized (depreciation) appreciation on investments

Other Affiliates [Member] | Fourth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]

330

(330)

Net unrealized (depreciation) appreciation on investments

Other Affiliates [Member] | Fifth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]

150

(150)

Net unrealized (depreciation) appreciation on investments

Other Affiliates [Member] | Sixth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]

Net unrealized (depreciation) appreciation on investments

$ 0

1,639

(848)

(791)

$ 1,639

$ 0

[1]	As of December 31, 2021 the Company no longer owns 5% or more of the portfolio company.

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Unrealized Gain (Loss) on Investments	$ (5,552)	$ 3,205	$ 313
Fair Value, Inputs, Level 1 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	1,300
Fair Value, Inputs, Level 1 [Member] \| Investment One [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		100
Fair Value, Inputs, Level 1 [Member] \| Investment Two [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		200
Fair Value, Inputs, Level 3 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	10
Unrealized Gain (Loss) on Investments	2,600	6,300
Fair Value, Inputs, Level 3 [Member] \| Debt [Member]
Unrealized Gain (Loss) on Investments	(21,000)	(5,600)
Fair Value, Inputs, Level 3 [Member] \| Equity Securities [Member]
Unrealized Gain (Loss) on Investments	(400)
Fair Value, Inputs, Level 2 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	$ 40	$ 100
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) \| $ / shares	$ 23.45
The 2026 Notes [Member] \| Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 53,900
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) \| $ / shares	$ 23.20
The 2027 Notes [Member] \| Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 53,400
Asset-backed Notes 2019 [Member] \| Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure, Total	42,600
Asset-backed Notes 2022 [Member] \| Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 100,000
Measurement Input, Hypothetical Market Yields [Member]
Debt Instrument, Measurement Input	0.25

Note 6 - Fair Value - Significant Level 3 Fair Value Measurment Inputs (Details) - Fair Value, Inputs, Level 3 [Member]
$ in Thousands

Dec. 31, 2022

USD ($)

Dec. 31, 2021

USD ($)

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member]

$ 716,319

$ 457,557

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member]

$ 669,617

$ 430,417

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member]

0.03

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member]

0.22

^[1]

0.23

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member]

0.14

0.12

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]

$ 16,545

$ 6,900

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]

0.10

0.20

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]

0.75

^[1]

0.50

Debt [Member] | Convertible Note Analysis [Member]

0.31

0.33

Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member]

$ 296

Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

168.93

Warrant [Member] | Black-scholes Valuation Model [Member]

168.93

Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]

$ 26,145

$ 19,837

Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]

0.28

0.25

Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]

0.20

Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]

0.00

Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]

Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]

1,899

^[1]

980.00

Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

^[1]

Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]

58.52

20.35

Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]

0.28

0.25

Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]

0.20

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member]

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]

$ 1,300

$ 200

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member]

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]

0.25

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member]

Equity Securities [Member] | Last Equity Financing [Member]

0.25

Equity Securities [Member] | Last Equity Financing [Member] | Minimum [Member] | Measurement Input, Share Price [Member]

$ 2,416

$ 203

Equity Securities [Member] | Last Equity Financing [Member] | Maximum [Member] | Measurement Input, Share Price [Member]

0.00

Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

1.00

Asset Coverage to Borrowings, Ratio, Percent

26.93

0.41

[1]	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Recurring [Member]
Investments, fair value	$ 720,026	$ 458,075
Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	7,066	7,868
Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	2,788	1,359
Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	686,458	437,317
Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	29,712	20,200
Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	2,556	358
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	140	155
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	140	155
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	3,567	363
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	7,066	7,868
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	2,788	1,359
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	3,567	363
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	716,319	457,557
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	716,319	457,557
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	686,458	437,317
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	26,145	19,837
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	$ 2,416	$ 203

Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 457,557	$ 350,048
Purchase of investments	421,978	344,445
Warrants and equity received and classified as Level 3	5,672	2,681
Principal payments received on investments	(95,871)	188,010
Proceeds from sale of investments	(49,835)	50,690
Net realized (loss) gain on investments	(9,094)	(2,519)
Unrealized (depreciation) appreciation included in earnings	(6,880)	3,885
Transfer out of Level 3	(1,371)	(303)
Transfer out of debt investments	0
Other	(5,837)	(1,980)
Balance	716,319	457,557
Principal payments received on investments	95,871	(188,010)
Proceeds from sale of investments	49,835	(50,690)
Debt [Member]
Balance	437,317	333,495
Purchase of investments	421,372	344,445
Warrants and equity received and classified as Level 3	0	0
Principal payments received on investments	(95,558)	188,010
Proceeds from sale of investments	(49,371)	47,436
Net realized (loss) gain on investments	(8,221)	(5,033)
Unrealized (depreciation) appreciation included in earnings	(10,044)	1,836
Transfer out of Level 3	0	0
Transfer out of debt investments	(3,200)
Other	(5,837)	(1,980)
Balance	686,458	437,317
Principal payments received on investments	95,558	(188,010)
Proceeds from sale of investments	49,371	(47,436)
Warrant [Member]
Balance	19,837	12,736
Purchase of investments	0	0
Warrants and equity received and classified as Level 3	5,664	2,681
Principal payments received on investments	0	0
Proceeds from sale of investments	(464)	3,241
Net realized (loss) gain on investments	264	2,514
Unrealized (depreciation) appreciation included in earnings	2,215	5,218
Transfer out of Level 3	(1,371)	(71)
Transfer out of debt investments	0
Other	0	0
Balance	26,145	19,837
Principal payments received on investments	(0)	0
Proceeds from sale of investments	464	(3,241)
Equity Securities [Member]
Balance	203	2,117
Purchase of investments	606	0
Warrants and equity received and classified as Level 3	8	0
Principal payments received on investments	0	0
Proceeds from sale of investments	0	0
Net realized (loss) gain on investments	0	0
Unrealized (depreciation) appreciation included in earnings	(401)	(1,682)
Transfer out of Level 3	0	(232)
Transfer out of debt investments	2,000
Other	0	0
Balance	2,416	203
Principal payments received on investments	(0)	0
Proceeds from sale of investments	(0)	0
Other Investments [Member]
Balance	200	1,700
Purchase of investments	0	0
Warrants and equity received and classified as Level 3	0	0
Principal payments received on investments	(313)	0
Proceeds from sale of investments	0	13
Net realized (loss) gain on investments	(1,137)	0
Unrealized (depreciation) appreciation included in earnings	1,350	(1,487)
Transfer out of Level 3		0
Transfer out of debt investments	1,200
Other	0	0
Balance	1,300	200
Principal payments received on investments	313	0
Proceeds from sale of investments	$ (0)	$ (13)

Note 7 - Borrowings (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands

12 Months Ended

24 Months Ended

21840 Months Ended

Feb. 25, 2022

Jun. 22, 2021

Apr. 24, 2021

Apr. 21, 2020

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Jun. 04, 2020

Feb. 25, 2022

Nov. 09, 2022

Jun. 15, 2022

Mar. 30, 2021

Dec. 31, 2019

Sep. 15, 2019

Aug. 13, 2019

Jun. 19, 2019

Dec. 31, 2018

Jun. 01, 2018

Oct. 11, 2017

Sep. 29, 2017

172.00%

$ 2,788

$ 1,359

^[1]

439,323

260,250

$ 187,625

$ 154,375

$ 127,875

Interest Paid, Excluding Capitalized Interest, Operating Activities

582,573

353,000

17,028

10,706

8,593

Reserve Cash Balance [Member]

Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature

$ 1,000

$ 500

Key Facility [Member]

$ 150,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 125,000

Line of Credit Facility, Advance Rate of Eligible Debt Investments

60.00%

Long-Term Debt, Weighted Average Interest Rate, over Time

5.33%

4.25%

Line of Credit Facility, Unused Capacity, Commitment Fee Percentage

0.50%

Line of Credit Facility, Current Borrowing Capacity

$ 120,000

$ 71,500

Line of Credit Facility, Remaining Borrowing Capacity

40,200

19,800

5,000

53,500

Key Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

$ 125,000

Key Facility [Member] | Prime Rate [Member]

3.25%

Debt Instrument, Variable Rate

0.25%

7.50%

3.25%

NYL Facility [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 200,000

$ 100,000

$ 200,000

$ 100,000

Line of Credit Facility, Current Borrowing Capacity

$ 23,200

$ 21,200

Line of Credit Facility, Remaining Borrowing Capacity

23,200

5,700

Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature

$ 200,000

Line of Credit Facility, Advance Rate

67.00%

Line of Credit Facility, Change in Maximum Borrowing Capacity

$ 100,000

Long-Term Line of Credit, Total

$ 176,800

$ 78,800

Line of Credit Facility, Interest Rate at Period End

5.57%

4.62%

$ 176,750

$ 78,750

NYL Facility [Member] | USD Mid-market Wwap Rate [Member]

200,000

100,000

Asset-backed Notes 2019 [Member]

3.00%

600

900

4.21%

42,600

70,500

Asset-backed Notes 2022 [Member]

$ 160,000

1,000

7.56%

100,000

The 6.25 % Notes Due 2022 [Member]

100,000

$ 157,800

6.25%

Adittional 2022 Notes [Member]

$ 32,500

$ 4,900

The 2022 Notes [Member]

6.25%

Debt Instrument, Convertible, Conversion Price (in dollars per share)

^[1]

$ 37,375

$ 25

Interest Paid, Excluding Capitalized Interest, Operating Activities

$ 37,400

300

Payments of Debt Issuance Costs

$ 400

The 2026 Notes [Member]

4.875%

^[1]

57,500

The 2026 Notes Underwriter Option [Member]

57,500

$ 57,500

Debt Instrument, Convertible, Conversion Price (in dollars per share)

$ 7,500

$ 25

The 2027 Notes [Member]

6.25%

57,500

^[1]

The 2027 Notes Underwriter Option [Member]

$ 57,500

$ 0

$ 50,000

Debt Instrument, Convertible, Conversion Price (in dollars per share)

$ 7,500

$ 25

Minimum [Member]

Asset Coverage to Borrowings, Ratio, Percent

150.00%

Minimum [Member] | Key Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

Minimum [Member] | Key Facility [Member] | Prime Rate [Member]

1.00%

Minimum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]

4.25%

Maximum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]

3.55%

2.75%

5.15%

3.25%

[1]	Total amount of senior securities outstanding at the end of the period presented.

Note 7 - Borrowings - Borrowings (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Nov. 09, 2022

Jun. 15, 2022

Dec. 31, 2021

Mar. 30, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

$ 582,573

$ 353,000

^[1]

439,323

260,250

$ 187,625

$ 154,375

$ 127,875

Unamortized debt issuance costs attributable to term borrowings

143,250

92,750

(5,245)

(2,637)

Total borrowings outstanding, net

434,078

257,613

Key Facility [Member]

125,000

5,000

53,500

120,000

71,500

NYL Facility [Member]

200,000

100,000

176,750

78,750

Asset-Backed Notes [Member]

23,250

21,250

42,573

70,500

42,573

70,500

Asset-backed Notes 2022 [Member]

100,000

$ 157,800

100,000

The 2027 Notes [Member]

57,500

$ 50,000

57,500

^[1]

The 2026 Notes [Member]

57,500

$ 57,500

^[1]

57,500

$ 0

[1]	Total amount of senior securities outstanding at the end of the period presented.

Note 7 - Borrowings - Senior Securities (Details) - USD ($)
$ / shares in Units, $ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

^[1]

$ 439,323

$ 260,250

$ 187,625

$ 154,375

$ 127,875

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 1,725

$ 1,943

$ 2,133

$ 2,192

$ 2,050

^[3]

$ 0

Credit Facilities [Member]

^[1]

$ 181,750

$ 132,250

$ 50,250

$ 17,000

$ 90,500

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 4,169

$ 3,823

$ 7,965

$ 19,908

$ 2,896

^[3]

$ 0

The 2027 Notes [Member]

$ 57,500

^[1]

$ 0

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 13,179

^[3]

Average market value per unit (in dollars per share)

^[4]

$ 24.09

The 2026 Notes [Member]

^[1]

$ 57,500

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 13,179

$ 8,793

^[3]

Average market value per unit (in dollars per share)

^[4]

$ 24.45

$ 25.90

The 2022 Notes [Member]

^[1]

$ 0

$ 37,375

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 0

$ 10,708

$ 9,055

$ 7,014

^[3]

$ 0

Average market value per unit (in dollars per share)

^[4]

$ 24.60

$ 25.53

$ 25.52

The 2022-1 Securitization [Member]

^[1]

$ 100,000

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 7,578

^[3]

$ 0

The 2019-1 Securitization [Member]

^[1]

$ 42,573

$ 70,500

$ 100,000

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 17,799

$ 7,171

$ 4,002

$ 3,384

^[3]

$ 0

[1]	Total amount of senior securities outstanding at the end of the period presented.
[2]	Asset coverage per unit is the ratio of the original cost less accumulated depreciation, amortization or impairment of the Company’s total consolidated assets, less all liabilities and indebtedness not represented by senior securities, to the aggregate amount of senior securities representing indebtedness. Asset coverage per unit is expressed in terms of dollar amounts per $1,000 of indebtedness.
[3]	The amount which the holder of such class of senior security would be entitled upon the voluntary liquidation of the applicable issuer in preference to any security junior to it. The “ — ” in this column indicates that the SEC expressly does not require this information to be disclosed for certain types of securities.
[4]	Not applicable to the Company’s credit facilities, 2019-1 Securitization and 2022-1 Securitization because such securities are not registered for public trading.

Note 8 - Federal Income Tax (Details Textual) - USD ($) $ in Millions	Dec. 31, 2022	Mar. 03, 2022	Dec. 31, 2021
Federal Excise Tax, Percent	4.00%	4.00%
Operating Loss Carryforwards	$ 18.8		$ 10.8
Sales and Excise Tax Payable	0.7		0.4
Tax Basis of Investments, Cost for Income Tax Purposes	721.2		453.8
Tax Basis of Investments, Gross, Unrealized Appreciation	18.5		13.0
Tax Basis of Investments, Gross, Unrealized Depreciation	$ 19.8		$ 8.7

Note 8 - Federal Income Tax - Reconciliation of Net Increase in Net Assets to Taxable Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net increase in net assets resulting from operations	$ 21,151	$ 27,782	$ 6,364
Net unrealized appreciation on investments	(5,552)	3,205	313
Other book-tax differences	3,292	1,462	782
Change in capital loss carry forward	9,484	3,643	14,698
Taxable income before deductions for distributions	$ 39,479	$ 29,682	$ 21,531

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Proceeds from Issuance of Common Stock

Note 8 - Federal Income Tax - Tax Characters of Distributions Paid (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Ordinary income	$ 31,490	$ 25,099	$ 21,592
Total	$ 31,490	$ 25,099	$ 21,592

Note 8 - Federal Income Tax - Undistributed Ordinary Income Earnings on a Tax Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Undistributed ordinary income	$ 18,813	$ 10,825	$ 6,242
Long term capital loss carry forward	(73,055)	(63,571)	(59,928)
Unrealized appreciation	18,542	12,973	9,578
Unrealized depreciation	(19,771)	(8,738)	(8,545)
Other temporary differences	11,875	7,465	5,983
Total	$ (43,596)	$ (41,046)	$ (46,670)

Note 9 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability	$ 1,761
Commitments to Extend Credit [Member]
Other Commitment, Total	$ 190,000	$ 114,500

Note 9 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Unfunded commitments, principal balance	$ 190,000
Fair value of unfunded commitment liability	1,761
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	21,000
Fair value of unfunded commitment liability	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	66
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	4,000
Fair value of unfunded commitment liability	72
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	22,500
Fair value of unfunded commitment liability	236
Engage3, LLC [Member]
Unfunded commitments, principal balance	8,000
Fair value of unfunded commitment liability	40
Groundspeed Analytics, Inc. [Member]
Unfunded commitments, principal balance	15,000
Fair value of unfunded commitment liability	150
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	88
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	65
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	72
Optoro, Inc. [Member]
Unfunded commitments, principal balance	15,000
Fair value of unfunded commitment liability	38
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	158
Robin Healthcare, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	100
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	64
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	25,500
Fair value of unfunded commitment liability	105
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	9,000
Fair value of unfunded commitment liability	$ 19

Note 10 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment Concentration Risk [Member]
Concentration Risk, Percentage	23.00%	26.00%
Investment Income Concentration Risk [Member]
Concentration Risk, Percentage	15.00%	17.00%	23.00%

Note 11 - Distributions (Details Textual) - $ / shares		9 Months Ended	12 Months Ended
Note 11 - Distributions (Details Textual) - $ / shares	Oct. 28, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)			$ 1.25
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.11	$ 1.28	1.28	$ 1.25	$ 1.25
Taxable Earnings Per Share, Basic (in dollars per share)			1.60
Earnings Per Share, Basic, Undistributed (in dollars per share)			$ 0.68

Note 11 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended	12 Months Ended
	Feb. 23, 2023	Oct. 28, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Distributions declared per share (in dollars per share)		$ 0.11	$ 1.28	$ 1.28	$ 1.25	$ 1.25
Dividends, cash			$ 29,619		$ 25,067
Dividends, shares (in shares)			55,095		28,057
Dividends, stock			$ 679		$ 460
Dividend Paid January 13, 2023 [Member] \| Subsequent Event [Member]
Distributions declared per share (in dollars per share)	$ 0.11
First 10/28/2022 Dividend [Member]
Record date				Feb. 17, 2023
Payment date				Mar. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
Second 10/28/2022 Dividend [Member]
Record date				Jan. 18, 2023
Payment date				Feb. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,021
Dividends, shares (in shares)				5,754
Dividends, stock				$ 74
Third 10/28/2022 Dividend [Member]
Record date				Dec. 19, 2022
Payment date				Jan. 13, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 2,978
Dividends, shares (in shares)				5,618
Dividends, stock				$ 69
Fourth 10/28/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.05
Dividends, cash				$ 1,319
Dividends, shares (in shares)				2,171
Dividends, stock				$ 27
First 7/29/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,638
Dividends, shares (in shares)				4,341
Dividends, stock				$ 57
Second 7/29/2022 Dividend [Member]
Record date				Oct. 18, 2022
Payment date				Nov. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,580
Dividends, shares (in shares)				4,621
Dividends, stock				$ 60
Third 7/29/2022 Dividend [Member]
Record date				Sep. 19, 2022
Payment date				Oct. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,558
Dividends, shares (in shares)				7,703
Dividends, stock				$ 81
First 4/29/22 Dividend [Member]
Record date				Aug. 18, 2022
Payment date				Sep. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,528
Dividends, shares (in shares)				4,925
Dividends, stock				$ 60
Second 4/29/2022 Dividend [Member]
Record date				Jul. 19, 2022
Payment date				Aug. 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,484
Dividends, shares (in shares)				3,939
Dividends, stock				$ 55
Third 4/29/2022 Dividend [Member]
Record date				Jun. 17, 2022
Payment date				Jul. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,434
Dividends, shares (in shares)				4,286
Dividends, stock				$ 51
First 2/25/2022 Dividend [Member]
Record date				May 18, 2022
Payment date				Jun. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,378
Dividends, shares (in shares)				4,428
Dividends, stock				$ 50
Second 2/25/2022 Dividend [Member]
Record date				Apr. 19, 2022
Payment date				May 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,349
Dividends, shares (in shares)				4,088
Dividends, stock				$ 49
Third 2/25/2022 Dividend [Member]
Record date				Mar. 18, 2022
Payment date				Apr. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,352
Dividends, shares (in shares)				3,221
Dividends, stock				$ 46
First 10/22/21 Dividend [Member]
Record date					Feb. 18, 2022
Payment date					Mar. 16, 2022
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,100
Dividends, shares (in shares)					3,409
Dividends, stock					$ 46
Second 10/22/21 Dividend [Member]
Record date					Jan. 19, 2022
Payment date					Feb. 16, 2022
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,096
Dividends, shares (in shares)					2,680
Dividends, stock					$ 43
Third 10/22/21 Dividend [Member]
Record date					Dec. 17, 2021
Payment date					Jan. 14, 2022
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,031
Dividends, shares (in shares)					3,417
Dividends, stock					$ 56
Fourth 10/22/21 Dividend [Member]
Record date					Nov. 18, 2021
Payment date					Dec. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.05
Dividends, cash					$ 1,013
Dividends, shares (in shares)					1,197
Dividends, stock					$ 20
First 7/23/21 Dividend [Member]
Record date					Nov. 18, 2021
Payment date					Dec. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,027
Dividends, shares (in shares)					2,395
Dividends, stock					$ 38
Second 7/23/21 Dividend [Member]
Record date					Oct. 19, 2021
Payment date					Nov. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,010
Dividends, shares (in shares)					1,907
Dividends, stock					$ 34
Third 7/23/21 Dividend [Member]
Record date					Sep. 17, 2021
Payment date					Oct. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,008
Dividends, shares (in shares)					2,068
Dividends, stock					$ 36
First 4/23/21 Dividend [Member]
Record date					Aug. 18, 2021
Payment date					Sep. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,996
Dividends, shares (in shares)					2,041
Dividends, stock					$ 34
Second 4/23/21 Dividend [Member]
Record date					Jul. 20, 2021
Payment date					Aug. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,983
Dividends, shares (in shares)					1,937
Dividends, stock					$ 34
Third 4/23/21 Dividend [Member]
Record date					Jun. 17, 2021
Payment date					Jul. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,964
Dividends, shares (in shares)					1,888
Dividends, stock					$ 33
First 2/26/21 Dividend [Member]
Record date					May 18, 2021
Payment date					Jun. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,964
Dividends, shares (in shares)					1,671
Dividends, stock					$ 29
Second 2/26/21 Dividend [Member]
Record date					Apr. 20, 2021
Payment date					May 14, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,937
Dividends, shares (in shares)					1,794
Dividends, stock					$ 29
Third 2/26/21 Dividend [Member]
Record date					Mar. 18, 2021
Payment date					Apr. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,938
Dividends, shares (in shares)					1,653
Dividends, stock					$ 28

Note 12 - Subsequent Events (Details Textual) - USD ($)
$ in Thousands

1 Months Ended

12 Months Ended

Feb. 24, 2023

Feb. 14, 2023

Feb. 03, 2023

Feb. 01, 2023

Jan. 24, 2023

Jan. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

$ 84,603

$ 30,086

$ 44,611

The 2021 Equity Distribution Agreement [Member]

^[1]

$ 439,323

$ 260,250

$ 187,625

$ 154,375

$ 127,875

Stock Issued During Period, Shares, New Issues (in shares)

3,982,684

Proceeds from Issuance of Common Stock

$ 50,300

Payments of Stock Issuance Costs

$ 1,000

Subsequent Event [Member] | Britecore Holdings, Inc. [Member] | Debt Investments [Member]

Payments to Acquire Investments, Total

$ 5,000

Subsequent Event [Member] | Noodle Partners, Inc. [Member] | Debt Investments [Member]

Payments to Acquire Investments, Total

$ 20,000

Subsequent Event [Member] | Canary Medical Inc. [Member]

Subsequent Event [Member] | Unagi, Inc [Member]

$ 7,500

$ 3,200

Subsequent Event [Member] | Embody, Inc. [Member]

$ 2,100